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EXECUTIVE SUMMARY 
Around 360,000 people in the UK were diagnosed with cancer in 2015. 36% of these people 
were 75 and over. By 2035, this proportion will rise to almost half (46%)1, because of the UK’s 
ageing population.  
As the patient population changes, services must adapt to make sure they are meeting every 
person’s needs and that no group is left behind. Now and in the future, it is crucial that older 
people with cancer are given the support they need to access the most appropriate treatment 
for them, and to have the best possible experience of care.  
In this instance, age is a proxy measure for complexity: increasing age is correlated with 
having multiple health conditions, cognitive issues or complex social care needs – all of which 
can require cancer treatment and care plans to be modified. However, it is important to note 
that this is not true for every person over 75 and there are many people under 75 who also 
have complex needs.  
 
However, it is also highly likely that this group of patients with more complex needs – and 
therefore many patients over 75 – are the ones who will be most affected by wider pressures 
facing the NHS. These pressures include severe shortages in key professional groups, as well 
as a lack of time for long consultations in the clinic and for cancer multidisciplinary teams 
(MDTs) to discuss patients’ cases. So although the recommendations in this briefing are 
targeted towards ensuring cancer services meet the needs of older people with cancer, if 
implemented many of them would benefit all patients in the NHS – of all ages.  
 
However, evidence shows that right now there are age-related inequalities in cancer 
outcomes. Cancer survival is generally lower for older patients and the discrepancy between 
the UK’s performance and the best-performing countries is worse for older patients than it is 
for younger patients2,3,4. Although overall cancer survival has doubled in the last 40 years, the 
discrepancy between cancer-specific survival for older and younger patients has persisted. If 
we are to achieve our ambitions of achieving world-class outcomes for everyone affected by 
cancer, it is vital that we improve the treatment and care of older patients.  
 
Older patients are also less likely to receive many different types of treatment5. Some of the 
variation in access to treatment can be accounted for by patients choosing not to pursue 
active treatment. This could be because they are simply too unwell or because, for example, 
they are prioritising maintaining a good quality of life and spending time with family over 
lengthening their life. However, there may also be some who are simply not being offered 
curative treatment that could benefit them, because assumptions have been made about 
their fitness based on their age. In contrast, we also heard anecdotally that some feel 
pressured by their clinicians to undergo intensive curative treatment. 
 
We must get this balance right. Treatment decisions should consistently be shaped around 
each person’s individual situation. Achieving this is, of course, important for every person 
diagnosed with cancer. However, it is most difficult to achieve this for those who have more 
complex medical or social needs, or who need more time and support to come to a decision 
about their treatment plan. This is the current challenge.    
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One reason for this –as highlighted by the 2015 Cancer Strategy for England6 – is that 
methods of assessing older patients are not fit for purpose, resulting in older people’s needs 
not being identified or sufficiently well-understood7. There are also issues with the knowledge 
and awareness of the cancer workforce about the specific challenges of treating older 
patients, and there is a lack of evidence to support new cancer treatments in older 
populations8. 
 
This report presents research commissioned by Cancer Research UK (CRUK) and conducted by 
the University of Birmingham’s Health Services Management Centre and ICF International, 
which sought to understand the specific needs of older patients, and to explore the process of 
clinical decision-making for older people with cancer across the UK. 
 
This research involved a literature review, clinical observations at eight case study sites, 
interviews with 15 national decision-makers and 80 health professionals, and three UK-wide 
surveys (of primary care professionals, secondary care professionals and older people 
affected by cancer). The direction of the research was also informed by engagement with a 
group of older people affected by cancer, and by extensive engagement and interviews with 
national policymakers. Full methodology is available in Appendix 1.  
 
OLDER PEOPLE AND CANCER 
In 2035, it is projected that around 234,000 cases of all cancers combined1 will be diagnosed 
in people aged 75 and over in the UK. People aged 75 and over are projected to account for 
46% of all cancer diagnoses and 62% of all cancer deaths9.  
Net survival is generally lower for patients over 75, with survival generally decreasing with 
increasing age – even after adjusting for mortality from causes other than cancer. Despite 
overall survival doubling over the past 40 years, the discrepancy between survival for older 
and younger patients has not improved10.  
There is also evidence that the gap between the UK’s cancer survival and that of the best-
performing countries is worse for older patients. For example, most of the survival difference 
for breast cancer between the UK and Ireland and the European average can be accounted 
for by the low survival of women age 75 and over11. In colorectal (bowel) cancer, five-year 
survival was 15% lower in UK patients aged 75 and older than the equivalent patients in 
Canada diagnosed between 2005-2007, while it was 9.5% lower for patients aged 15-4412.  
There are several reasons why this is the case. For example, older people are more likely to 
have poorer overall health, and are more likely to be diagnosed in an emergency, which is 
associated with being diagnosed at a later stage, and with poorer survival13. Between 2006 
and 2015, 41% of all cancers in those aged 80-84 were diagnosed in an emergency in England, 
compared with 14% of cancers in those aged 50-59. Although there is a clear need to improve 
early diagnosis of cancer in older patients, that is outside of the scope of this briefing.  
However, there are also discrepancies in access to treatment for older people with cancer. A 
report by the National Cancer Information Network (NCIN) and CRUK found that across 20 
                                                     
1 Around 130,000 in males and around 104,000 in females 
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cancer sites, older patients were less likely to have major surgical resections14. It has also 
been reported that the use of chemotherapy declines with age, in several types of cancer15. 
Other studies have found similar; for example, older women with breast cancer are less likely 
to undergo surgery16; the use of radiotherapy also gradually decreases with age17. Older 
people with lung cancer have also been shown to be far less likely to undergo surgery18.  
In some cases, there are legitimate reasons for these lower treatment rates. For example, 
older patients are more likely to have other health conditions, which could mean they are 
unable to tolerate either the treatment itself, or the side-effects of the treatment19,20,21. Some 
studies have adjusted for comorbidities and have still found variation in access22,23 –
suggesting there could be some inappropriate decision-making based on chronological age.  
 
However, some patients may also choose not to pursue curative treatments, for various reasons. 
Recent research has found that when considering chemotherapy, over half of older patients 
surveyed prioritised outcomes other than survival, for example maintaining their quality of life, 
independence or cognitive abilities24. 
 
FINDINGS AND RECOMMENDATIONS 
OLDER PATIENTS OFTEN HAVE MORE COMPLEX CARE NEEDS – AND 
THE SYSTEM IS NOT SET UP TO DEAL WITH THEM 
 
Older people with cancer are more likely to have complex medical and social needs, which 
can mean they require additional support to access treatment.  
 
For example, older patients are more likely to have other age-related illnesses, but also more 
likely to require social care support. Furthermore, up to 40% of older patients present with 
cognitive issues that can impair their capacity to make complex decisions about treatment, 
adhere to treatment plans and recognise symptoms of toxicity that might require medical 
attention25.  
 
Through our engagement with health professionals as part of our research, we identified four 
main clinical factors which tend to impact the treatment options for older patients: 
1. The patient’s fitness to withstand the rigours of treatment 
2. The likelihood that the patient will die from a cause other than their cancer  
3. Whether the patient has comorbidities 
4. If there is clinical evidence to support a particular course of treatment in an older 
patient 
Many older people with cancer also have additional social support needs. For example, they 
might care for a loved one or themselves require carer support. This can also impact 
treatment choices. The older people affected by cancer involved in our research told us that 
uncertainty about how they would access non-medical support can be a major barrier to 
accessing treatment. Similarly, 46% of cancer multidisciplinary team (MDT) members 
surveyed for this research identified a lack of social or practical support as a barrier to older 
people accessing the most effective treatment for their cancer. 
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Unfortunately, the support patients need is often not available. Although our interviewees 
valued community-based support such as oncology nurses or convalescence homes, 
availability of this support is variable. Although patients can sometimes arrange their own 
alternative care, cost can often be a major barrier.   
 
This speaks to a much broader issue with social care, which is crucially important but outside 
the scope of this research. However, there are defined actions that could help make sure all 
the support needs of people with cancer are met throughout treatment and recovery. For 
example, an earlier assessment of a person’s support needs would help ensure there is 
enough time to plan support required for the weeks following a major operation. 
 
Cancer services could also do more to embed consideration of the specific needs of older 
people with cancer in how services are planned and delivered. Where there are service 
reconfigurations, there must be a recognition that older patients are more likely to require 
additional support to travel to treatment. For example, our interviewees based at sites where 
patients are more likely to have to travel for treatment – such as tertiary centres serving a 
mostly rural area – expressed concerns that older patients could be excluded from treatment, 
or from taking part in clinical trials.  
 
So yes, it is more difficult for older people to get transport and it’s possible that a lot of 
them don't want to be a bother to their families …getting on buses, trains, whatever, is 
not ideal and the kind of ambulance, minibus service trails them round the country so 
they don't like that … it’s another burden that they have. (Medical oncologist) 
 
In England, where radiotherapy services are soon to be re-organised into new Radiotherapy 
Networks, there is a timely opportunity to embed the needs of older people with cancer in 
this process, through meaningful patient involvement as services are planned.  
 
1.  Cancer service managers should ensure that patients’ support needs are assessed at an 
early stage in the pathway, so that they are able to access the support they need during and 
after completing treatment. Health service regulators should consider ways to ensure that 
this is done effectively and consistently across the UK.  
 
2. UK health services should ensure that the specific needs of older patients are considered 
in all new service plans and workforce plans. For example, emerging Radiotherapy 
Networks in England should consider the impact of changing travel requirements on older 
patients and should work with charities and providers to ensure all patients are given the 
support they need to receive treatment. 
 
 
TREATMENT DECISION-MAKING DOES NOT ALWAYS TAKE ALL 
RELEVANT FACTORS INTO ACCOUNT 
We can only be sure that treatment decisions are right for patients if we are confident that 
the decisions take into account all relevant information about that person. This is true for 
every patient, but is particularly important for patients with additional medical and social 
Advancing Care, Advancing Years 11 
needs – which will include many older people.  
 
Unfortunately, these complex needs are often not routinely considered as part of the 
treatment decision-making process in cancer. This is partly because services lack the right 
tools to assess frailty in the cancer setting, and Comprehensive Geriatric Assessments are still 
rarely used in oncology. This is important: it is widely recognised that chronological age alone 
is not a strong indicator of how well a person will tolerate cancer treatment26. 
 
Frailty assessments can be used to predict how well a patient will be able to tolerate 
treatment, or to help assess what additional support could help them. In the absence of a 
robust method, assessment of a patient’s fitness for treatment can instead be assumed based 
on their age, or simply a subjective assessment of how they seem during a consultation.  
 
Our research also found that Comprehensive Geriatric Assessments – or CGAs – are rarely 
used in oncology. A CGA supports clinicians by providing an evidence-based assessment of 
frailty, reducing the subjectivity of the assessment, and helps make sure care is centred 
around the patient and their individual needs. 
 
While 70% of primary care staff surveyed told us that their assessment of a patient’s frailty 
impacts their decision-making, we found very limited evidence of CGA usage and low 
awareness of the tools available. Similarly, although the most significant factor in clinical 
decision-making identified by multidisciplinary team (MDT) meeting members was frailty, 
CGAs were used in few of the sites we observed as case studies. We also heard that many 
clinicians were unconvinced of the value these tools would add, or thought they would not be 
worth the extra resources required to implement. Clinicians often tended to favour more 
informal, intuitive assessment rather than a robust and formal tool. 
 
I mean certainly the data would suggest it (primary care frailty assessment) may be 
part of the problem. If you look at the sort of the cancer outcomes and sort of stages at 
presentation, clearly there is a bias and we are serving our elderly patients less well 
than we are their younger compatriots.  
(National interviewee) 
 
These findings are disappointing, however unsurprising: although there is widespread 
consensus about the value of CGAs in general, and evidence of their beneficial impact in 
oncology, there is no clear evidence regarding the best tool to use27 and they have not been 
fully integrated into oncology practice28. Although there are several pieces of guidance about 
conducting CGAs in cancer, their use is still highly variable – often because of a lack of staff, as 
well as other institutional and/or funding constraints29. 
However, there is clear value in their use: case study sites that had embedded geriatrician-led 
multidisciplinary CGA clinics into the decision-making process did report better improved 
adherence to chemotherapy and increased rates of surgery30.  
 
3.  UK health services should pilot the routine usage of geriatric assessments for older 
people with cancer and should seek to gather further evidence of the relative benefits of 
different tools.  
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THE RIGHT INFORMATION DOES NOT ALWAYS GET TO THE RIGHT 
PEOPLE TO SUPPORT CLINICAL DECISION-MAKING 
There are also systemic issues in cancer services that limit the amount of information that is 
available to support clinical decision-making. Again, these issues apply to all patients – but are 
felt more acutely in more complex cases, and therefore often in older patients. For example, 
patient data is often not shared between the full range of health professionals caring for a 
patient, or even with the patient themselves.  
 
INFORMATION DOES NOT FLOW FROM PRIMARY CARE TO 
SECONDARY CARE 
37% of patients diagnosed in England in 2015 were diagnosed through an urgent GP referral, 
known as the “two-week wait”31, a route attached with targets in England and Wales 
requiring patients to be seen within two weeks of GP referral. These referrals are processed 
using forms, which are specific to each suspected type of cancer and differ between trusts 
and regions. These forms are brief and thus there is no space for primary care staff to 
communicate people’s personal circumstances, comorbidities, their frailty or other medical 
history. This means that the clinicians making decisions about patients’ treatment often do 
not have advanced access to information that could later prove critical – and so the person’s 
age is more likely to be used as a surrogate measure for their overall health. 
 
It doesn’t say what medication they’re on, what are their comorbidities, what are the 
real issues, what are the social factors, doesn’t tell anything about the person, it just 
tells you potentially what could be related to the disease. (National Interviewee) 
 
A relatively simple change to these forms could result in a significant improvement in the 
amount of information available to inform treatment decisions – for all patients. As forms 
differ from region to region there are some notable examples of good practice, where those 
making referrals have space for additional information – but this has not been done 
consistently. For example, a pilot in Leeds developed a digital solution that automatically 
populates the form with all required information32. There may also be cases where a referring 
GP has included information in a letter, but this has been lost in the system. 
 
4. Cancer Alliances and devolved cancer networks should explore digital solutions for 
ensuring that suspected cancer GP referrals can consistently incorporate additional 
information that could prove relevant to a future cancer treatment plan. 
 
THE RIGHT INFORMATION IS OFTEN NOT INCLUDED IN MDT 
DECISION-MAKING 
Every patient diagnosed with cancer in the UK has their case discussed at a MDT meeting. An 
MDT is made up of a variety of health professionals involved in treating and caring for 
patients. The MDT meets, most often weekly, to discuss individual patients’ cases and make 
treatment recommendations.   
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If MDTs are to make a treatment recommendation that is truly appropriate for the patient, 
they must have include all relevant information. But recent research by CRUK found that only 
14% of MDT discussions included information that did not specifically relate to the patient’s 
tumour33.   
 
While many MDT members see this as a responsibility of Clinical Nurse Specialists (CNS), 
nurses did not contribute information in over 75% of the meetings observed in our research. 
This reflects the lack of time available for full discussion of complex patients in MDT meetings, 
rather than a lack of willingness to contribute: the average discussion observed in our past 
research lasted just 3.2 minutes, in meetings lasting up to five hours, and each discussion 
included an average of just three people – although an average of 14 people were in 
attendance.  
 
This pressure has major implications for the quality of treatment decision-making. Not 
including important information about a patient – such as their preference, their psychosocial 
situation or their comorbidities – is poor for patients and also poor for MDT efficiency: past 
research has found that between 10 and 15% of recommendations made by an MDT were not 
implemented because they were later found to be inappropriate for the patient34,35. It is likely 
that this is a direct consequence of the MDT not taking all relevant information about the 
patient into account. When that additional information becomes apparent, patients are 
either discussed again by the MDT – adding a delay to their treatment – or a decision is made 
solely by their individual clinician, who might lack the expertise to know how to incorporate 
this information into the treatment plan. 
 
There is a clear need to reform and streamline MDTs, so that more time is available to discuss 
the most complex patients in enough depth – and therefore, many older patients. It is also 
important that MDTs consistently have access to all relevant information about the patients 
they discuss, so that they can make treatment recommendations that are tailored to the 
patient’s individual circumstances.  
 
While 54% of MDT members already use a type of proforma to feed information into the 
MDT, this does not happen consistently and there is no national guidance on their content. 
81% of MDT members surveyed in our past research2 felt that using a proforma would have a 
beneficial impact on meeting efficiency, by minimising the chance of the patient returning to 
the MDT for re-discussion after the first recommendation was rejected.  
 
5. UK health services should lead the development of national proforma templates, to be 
refined by MDTs. MDTs should require incoming cases and referrals to have a completed 
proforma with all information ready before discussion at a meeting. 
COMMUNICATION FROM SECONDARY CARE TO PRIMARY CARE 
SHOULD BE IMPROVED 
From our surveys of clinicians, we also identified an issue with the flow of information from 
secondary care back to primary care. This is important: although cancer care is managed 
primarily by cancer clinicians, patients’ other health conditions might still be managed in 
                                                     
2 1,258 respondents. Full results available at cruk.org/mdts-research 
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primary care. Patients may also seek advice from primary care about their treatment options 
or any side-effects they are experiencing.  
 
Although clinicians should inform GPs of a cancer diagnosis within 48 hours, this does not 
happen uniformly. Primary care staff also told us they would value additional information 
about a patient’s prognosis, their treatment options and their wider care plan.  
 
… it is not uncommon for somebody to be in floods of tears in the car on the way home 
from the hospital, phoning the GP, asking for an urgent appointment to talk things 
through but the GP didn’t even know they had a cancer diagnosis and wouldn’t have 
been told for days, sometimes weeks. (National interviewee and General Practitioner) 
 
6. Healthcare providers must ensure that primary care staff are updated on the outcome of 
patient discussions in a timely manner. This should include widespread use of digital 
solutions. 
PRESSURES ON ONCOLOGY SERVICES LIMIT THE QUALITY OF 
DECISION-MAKING AND COMMUNICATION BETWEEN OLDER PEOPLE 
WITH CANCER AND THEIR CLINICIANS  
The concept of shared decision-making (SDM) originated in the disability rights movement 
and is now ingrained into the ethos of health services, through the concept of ‘no decision 
about me without me’. The Health Foundation and NICE define SDM as ‘a process in which 
clinicians and patients work together to select tests, treatments, management, or support 
packages, based on clinical evidence and patients’ informed preferences’36.  
There is strong evidence that shared decision-making is beneficial for people with cancer37, 
for example because it can improve people’s experience of care38. However, achieving SDM 
can be more difficult in patients with multiple health conditions39, 40,41, cognitive impairment, 
social support needs and caring responsibilities42. This is therefore more likely to be the case 
for older people with cancer.  
 
The older people with cancer who responded to our survey often reported negative 
experiences with decision-making and some also reported feeling like their questions were 
not welcomed. We also heard that conversations focused too much on benefits of treatment, 
glossing over potential side-effects or long-term consequences.   
 
Mostly, it was assumed that I would do whatever they suggested - whilst I was not 
unhappy with what was being offered, as I knew that there were not a lot of options, I 
do not feel in hindsight that I was given much choice or indeed support in making such 
a choice. (A patient) 
 
These difficulties are exacerbated by time pressure in a treatment consultation – and this was 
reflected in our engagement with both older patients and clinicians. While a lack of time 
effects all patients, there is a greater impact on patients with complex needs, comorbidities 
or cognitive issues – and therefore, again, many older people with cancer.  
 
Today I had a patient who has cancer but has other comorbidities … so I had to discuss 
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that … and make it clear to them that these are the risk factors, these are the things 
that go wrong … that 20/30 minutes … just gets dragged on to 45 minutes. We can’t 
just stop the consultation because it’s been running out of time. (Anaesthetist) 
 
7. Cancer MDT leads and service managers should consider reviewing the length of 
consultation slots, factoring in additional time for more complex patients, and providing 
additional support before, during and after consultations for those who are living with 
frailty or have multiple comorbidities. 
Cancer treatment decision-making in the UK is also strongly impacted by national treatment 
targets. Several members of cancer MDTs interviewed for this study raised the issue of 
national treatment targets creating unhelpful pressure, for two reasons: firstly, through 
putting patients under pressure to make a quick decision, but secondly by limiting 
opportunities for testing patients’ likelihood to be able to tolerate treatment, and then to 
tailor their plan accordingly.  
They’re guidelines not tramlines and I think people get so caught up in that, that you 
forget the patient may not want to work in the timescale that the guidelines say. 
(National interviewee)  
 
This has been echoed in research, which has found that service targets that focus resource 
solely on cancer can disadvantage patients with complex wider needs, as individual clinicians 
may struggle to deliver effective treatment plans without breaching targets43. 
 
8. In ongoing reviews of cancer waiting times targets, UK health services should consider 
ways to ensure optimal treatment access, a positive experience and better outcomes for 
older people with cancer. 
THE CANCER WORKFORCE COULD BETTER SUPPORT THE NEEDS OF 
OLDER PATIENTS 
Cancer services in the UK are experiencing severe workforce gaps across many key 
professions, which is having a real impact on the ability to diagnose and treat cancer quickly, 
as well as to give patients the best possible experience of care44.  
 
There are also broader issues relating to the preparedness of the workforce to treat the 
growing number of older patients, including deficits in education, knowledge and attitudes 
and in the development or specific roles and services that meet older people’s needs45. For 
example, a 2013 survey of UK medical oncology trainees found that only 27.1% were 
confident in assessing risk to make treatment recommendations for older patients, compared 
to 81.4% being confident about treating younger patients46. 
 
For people with complex needs, it is critical that health professionals with specialist expertise 
are available to support them throughout treatment decision-making and treatment itself. 
There is also some evidence of benefit in providing additional specialist support, targeted to 
groups of older people with complex needs, who are at risk of undertreatment47.  
Specialist cancer nurses are a particularly critical workforce group for all patients, acting as a 
‘key worker’ throughout diagnosis, treatment delivery and palliative care. Patients and health 
professionals praised the value of nurses consistently throughout this research.  
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When I was first diagnosed 7 years ago there was no CNS in haematology at our local 
hospital and until I was referred elsewhere, I didn't realise these amazing nurses 
existed. Fortunately, we have a wonderful CNS now who is available by phone or e-
mail whenever needed. (Cancer patient, patient survey)   
 
The 2015 Cancer Strategy for England recommended that all patients are given a named 
Clinical Nurse Specialist (CNS) or key worker to contact. Scotland have also made a strategy 
commitment to put the necessary levels of training in place to ensure that by 2021, people 
with cancer who need it have access to a specialist nurse during and after their treatment and 
care. However, there are significant shortages in the CNS workforce across the UK. Whilst the 
proportion of patients in England having access to a CNS has risen from 84% in 2010 to 90% in 
201648, there is still variation across geographies and across different cancer sites. 84% of 
patients in Scotland reported access to a CNS in 2015/1649; in Wales in 2016, 81% reported 
access and in Northern Ireland in 2015, this figure was just 72%.  
Staffing issues were also recognised by national interviewees for this project, particularly for 
rarer cancers. This was echoed by a recent census by Macmillan Cancer Support, which found 
that up to 15% of cancer nursing roles in England are unfilled, and that there is wide 
geographic variation50. While supporting older patients is the responsibility of all staff – 
across primary, secondary and tertiary care – the nursing workforce is especially crucial for 
those in hospital care, and so this must be addressed as a matter of urgency.  
Frequently there’s just one of these nurses in a team and therefore once they’re on 
holiday or they’re sick there’s no back up, there’s nothing else, there’s nobody else who 
can step in. (National Interviewee) 
 
Furthermore, the role of a CNS is highly variable; their job titles and expectations are often 
inconsistent. Because of wider pressures, CNSs frequently fill service gaps in their local 
centres, rather than doing the work that best fits their expertise and training. A survey 
conducted as part of CRUK’s 2017 research into the non-surgical oncology treatments 
workforce found that 50% of CNSs did not feel they had enough patient-facing time and were 
consistently working an average of 5 additional hours each week – on average, 15% of their 
working hours51. 
 
Geriatricians are also important for the medical and social care of older patients, however are 
not always involved in cancer-specific care. Interviewees in both primary and secondary care 
noted the value of requesting geriatric consultant reviews – although few MDT members had 
done this in practice. The role of geriatricians in cancer care should be a key consideration 
throughout all cancer workforce planning, and especially in Health Education England’s phase 
II cancer workforce plan.  
 
9. Health Education England, and its equivalents in the devolved nations, should use the 
Cancer Research UK ‘best practice treatment model’ to project required workforce numbers 
based on patient demand, not on affordability52. Organisations should also include 
consideration of the specific needs of older people with cancer in all future workforce 
plans.  
WE NEED TO IMPROVE HOW INNOVATION REACHES OLDER PEOPLE  
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GETTING THE RIGHT EVIDENCE  
Research is the key to improving outcomes for all people affected by cancer. However, older 
patients are typically under-represented in clinical trials53, which can have strict inclusion 
criteria based on chronological age, comorbidities or cognitive ability. These factors combined 
mean that there is often relatively limited evidence on the specific effects of treatment on 
these patients.  
 
This means that decisions about treatment for patients with comorbidities – and therefore 
often older patients – cannot always be based on strong evidence. At least, not in comparison 
to decisions for their younger or otherwise fit counterparts.   
 
The most important thing is we don’t have any evidence for such patients… the number of 
patients who are [in] clinical trials above 75 years of age is far and few between and no 
meaningful conclusions can be made on that. (Medical oncologist) 
 
More could still be done to gather evidence, including boosting numbers of older patients in 
trials – but also doing research that enables patients with comorbidities or frailty to receive 
optimal treatment, through understanding the interactions at play.  
 
There is appetite for change: 70% of European health professionals responding to the 
PREDICT study in 2014 did not did not believe the present arrangements for clinical trials 
relating to older people to be satisfactory, and 60% believed that either European or national 
regulation of clinical trials should be amended to ensure greater representation of older or 
less fit patients54.   
 
Most clinical trials funded by Cancer Research UK do not have an upper age limit, when age 
limits are applied, researchers are asked to justify the boundary selected. Exclusion criteria 
relating to comorbidities or patient fitness are used in some trials where they risk 
confounding results or adding a safety risk, however, and comorbidities do increase with age. 
CRUK also fund some trials that ask specific questions about treatment for older patients, or 
patients who are less fit.  
 
The question remains about how best to ensure that there is sufficient evidence of a 
treatment’s efficacy in patients who are frail, have comorbidities or are elderly. One answer is 
for researchers to identify the priority questions for each cancer type, and to investigate 
these in clinical trials.  
APPROVING NEW TREATMENTS 
35% of respondents to our survey of MDT members felt that a lack of clinical evidence about 
the efficacy of treatment in an older population was a barrier to treatment. This is particularly 
problematic in cancers where there is a poorer understanding of the disease and its 
progression. This can make it difficult for clinicians to assess the risks of treatment and to 
weigh that up against the potential benefit to the patient. However, this is likely part of a 
broader issue about evidence in comorbid populations, rather than being related solely to 
chronological age.    
 
There is also scope for making changes to the process of approving new treatments so that it 
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better supports older people with cancer, who may value outcomes other than just improving 
survival – such as maintaining a good quality of life, their independence and cognition55. For 
example, national drug approvals should consider incorporating a broader range of evidence, 
including impact on quality of life – which was recommended in the Life Sciences Industrial 
Strategy56, although the recommendations were not specifically targeted towards older 
patients.  
 
There is also broader scope for incorporating real-world evidence (RWE) of a drug’s 
effectiveness in all patients. Under the current system, national approval bodies (such as NICE 
in England or the Scottish Medicine Consortium) must make their decision at a single point in 
time – often based on a relatively narrow scope of evidence. The price of the drug is then 
fixed, irrespective of how effective it proves to be in routine use. We would like to see 
broader use of managed access schemes like England’s Cancer Drugs Fund, which allow 
earlier access to a new drug while further evidence of its effectiveness on all patients is 
gathered in the NHS. This RWE is then combined with clinical trials data and incorporated into 
a final decision about approval and pricing.    
 
In the longer term, we encourage UK health services to explore the use of flexible pricing 
mechanisms such as outcomes-based pricing, in which the price of a drug can be reviewed at 
agreed stages and aligned directly to patient benefit, being increased or decreased based on 
emerging new data. This would ensure pricing and access decisions are grounded in the real 
experiences of patients. To take this forward, Cancer Research UK are exploring the feasibility 
of outcomes-based pricing through a commissioned research project, in partnership with the 
Greater Manchester Health and Social Care Partnership. 
HIGH-QUALITY DATA 
A key enabler to this is robust, routinely collected data about cancer treatment and 
outcomes. This is not an age-specific issue as it would significantly improve our ability to 
understand the effects of treatment on all patients. All UK organisations responsible for 
collecting health data should ensure significant resource is provided for improving the quality 
and completeness of treatments datasets. Having robust data about treatments and 
outcomes would enable more in-depth analyses of the extent of variation in access to 
treatment and outcomes for older patients, which could supplement clinical trial data and 
support efforts to benchmark services.  
 
10. Research funders should explore how to ensure more proportionate recruitment of 
older people with cancer into clinical trials, and how to ensure that research addresses any 
evidence gaps in the effectiveness of treatment in older patients, or those with 
comorbidities more broadly.  
11. National drug appraisal bodies should explore what alternative metrics could be 
considered during appraisals that would be more relevant to all patients, including older 
patients – such as quality of life and activities of daily living. 
  
Advancing Care, Advancing Years 19 
1 . BACKGROUND  
1.1 OLDER PEOPLE WITH CANCER IN THE UK 
Around 360,000 people in the UK were diagnosed with cancer in 2015. By 2035 this number 
could reach 500,000 – mostly because of the ageing population, but also partly due to 
lifestyle changes.  
In 2015, around 36% of people diagnosed with cancer were over 75. In 2035, it is projected 
that around 46% of cases of cancer will be diagnosed in people aged 75 and over in the UK. 
People aged 75 and over are projected to account for 46% of all cancer diagnoses and 62% of 
all cancer deaths57.  
FIGURE 1: PROJECTED DEMOGRAPHICS FOR CANCER INCIDENCE AND MORTALITY IN 2035 
 
Net survival is generally lower for patients over 75, with survival generally decreasing with 
increasing age – even after adjusting for mortality from causes other than cancer. Despite 
overall survival doubling over the past 40 years, the discrepancy between survival for older 
and younger patients has not improved58.  
There is also evidence that the gap between the UK’s cancer survival and that of the best-
performing countries is worse for older patients. For example, most of the survival difference 
for breast cancer between the UK and Ireland and the European average can be accounted 
for by the low survival of women age 75 and over59. In colorectal (bowel) cancer, five-year 
survival was 15% lower in UK patients aged 75 and older than the equivalent patients in 
Canada diagnosed between 2005-2007, while it was 9.5% lower for patients aged 15-4460.  
There are several reasons why this is the case. For example, older people are more likely to have 
poorer overall health, and are more likely to be diagnosed in an emergency, which is associated 
with being diagnosed at a later stage, and with poorer survival61. Between 2006 and 2015, 41% 
of all cancers in those aged 80-84 were diagnosed in an emergency, compared with 14% of 
cancers in those aged 50-5962.  
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FIGURES 2 AND 3: FIVE-YEAR SURVIVAL FOR MEN AND WOMEN DIAGNOSED BETWEEN 
2011 AND 2015 
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However, there are also discrepancies in access to treatment for older people with cancer63. 
For example, a recent report by the National Cancer Information Network (NCIN) and Cancer 
Research UK (CRUK) found that across 20 cancer sites, older patients were less likely to have 
major surgical resections64. Other studies have found similar; for example, older women with 
breast cancer65 are less likely to undergo surgery; the use of radiotherapy also gradually 
decreases with age66. Older people with lung cancer have also been shown to be far less likely 
to undergo surgery67. There is also evidence that usage of chemotherapy with curative intent 
for lung68.69,70, breast and colorectal cancer71, and as adjuvant therapy for breast cancer7273, 
declines with age.  
However, we must bear in mind that in some cases there are legitimate reasons for lower 
treatment rates in older populations. Older patients are more likely to have multiple health 
conditions, for example, which may impact treatment tolerance and therefore the treatment 
options themselves74,75,76. 
Some patients may also choose not to pursue curative treatments, for various reasons. 
Recent research has also found that when considering chemotherapy, over half of older 
patients surveyed prioritised outcomes other than survival, for example maintaining their 
quality of life, independence or cognition77. 
While this can explain some findings, some studies have adjusted for these factors and have 
still found variation. For example, one study examining breast cancer surgery found that 
‘inappropriate undertreatment’ was occurring for women over 8578, after adjusting for health 
measures and patient preferences in treatment decisions. Similarly, a small study looking at 
the use of chemotherapy and biological treatment in early-stage breast cancer found that age 
was a major factor in clinical judgement, irrespective of other factors such as age or tumour 
size79. 
Given these disparities in access, this study sought to identify the barriers that older patients 
face in accessing treatment, to examine clinical decision-making and recommend solutions 
that would ensure older people with cancer can access the right treatments for them. 
1.1 THIS RESEARCH 
Cancer Research UK commissioned an independent research team from the University of 
Birmingham’s Health Service Management Centre and ICF International for this research.  
The aim of the project was to understand clinical decision-making for older people with 
cancer across the UK and to identify barriers to optimal decision-making.  
This report presents evidence from the following: 
- A review of the literature relevant to clinical decision-making for older people with 
cancer  
- Qualitative interviews with representatives of Royal Colleges and professional 
organisations, researchers and policymakers (n=15) 
- Qualitative interviews with cancer multidisciplinary team members, primary care staff 
and other health professionals involved in clinical decision-making across eight UK 
sites (n=80) 
- A survey of cancer multidisciplinary team members (n=57) 
- A survey of primary care health professionals (n=98) 
- A survey of older people affected by cancer (n=50) 
- Observations of three multidisciplinary team meetings and three multidisciplinary 
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clinics 
The report presents these findings alongside additional Cancer Research UK policy research 
into improving the effectiveness of cancer multidisciplinary teams (MDTs) (“Meeting Patients’ 
Needs) and the non-surgical oncology workforce (“Full Team Ahead”).  
Further detail on the methodology is available in Appendix 1. 
1.2 TREATMENT DECISION-MAKING FOR OLDER 
PEOPLE WITH CANCER 
This research focused on understanding the process of making an initial treatment plan for 
older people with cancer. In most cases, an initial treatment recommendation is made by a 
cancer multidisciplinary team (MDT), before a final decision on is made by the treating 
clinician, in partnership with the patient and their loved ones. 
1.3 THE ROLE OF THE MULTIDISCIPLINARY TEAM  
Before beginning treatment, the vast majority of patients are discussed at a multidisciplinary 
team (MDT) meeting. In this meeting, a wide range of health professionals meet to make 
recommendations regarding patients’ treatment and care. MDT working is a central tenet of 
cancer services and the 2015 Cancer Strategy for England described MDTs as the ‘gold standard’ 
for cancer patient management. However, recognising the significant challenges faced by MDTs 
today, the strategy also made several recommendations for change. The most recent Welsh 
cancer strategy stated that MDTs remain the cornerstone of patient management in secondary 
care, and set out the intention to enhance their role as vehicles for governance and 
improvement80. A recent Cancer Research UK report recommended new ways of working for 
multidisciplinary team meetings, to allow more time for discussion of the most complex patients – 
including older patients81.  
Understanding how the different professional groups perceive MDT working and its impact on 
decision-making is an area acknowledged as being ‘under researched’82,83. However, evidence 
suggests there are benefits of involving geriatricians in MDT meetings, to support discussions 
of how treatments might interact with comorbidities and subsequent support needs84.  
1.4 GERIATRIC ASSESSMENTS 
Comprehensive Geriatric Assessments (CGAs) exist to support clinicians in making evidence-
based treatment decisions for older people, by providing a systematic framework that 
removes some of the subjectivity involved in assessing an older patient. Although these 
assessments vary, they most often involve assessing functional status and cognition85. They 
also often include fatigue, comorbidity, cognition, mental health status, social support, 
nutrition and geriatric syndromes86. 
Such tools are also an important way of ensuring care is centred around the patient and their 
individual needs. Patient-centred care is a central pillar of the NHS Constitution, in the form 
of the principle “no decision about me without me”.  
The International Society of Geriatric Oncology (SIOG), the European Society of Breast Cancer 
Specialists (EUSOMA), the European Organisation for Research and Treatment of Cancer 
(EORTC) and the US National Comprehensive Cancer Network (NCCN) now recommend the 
use of some form of geriatric assessment to help determine the best cancer treatments for 
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older patients, particularly for whom chemotherapy is considered. A CGA is now the most 
commonly cited and validated example of a geriatric assessment.  
The British Geriatrics Society have issued a good practice definition for CGAs: 
Despite their wider endorsement, CGAs are still not routinely used in oncology and there is no 
standardised method for conducting CGAs87. Although there is general consensus about 
which domains should be assessed88, there is little consensus on what constitutes a 
‘comprehensive’ assessment or the most effective measurement tools.  
1.4.1 COMPREHENSIVE GERIATRIC ASSESSMENTS IN ONCOLOGY 
At present there is no clear evidence regarding the best tool to use for CGAs in oncology, or 
how oncology outcomes are improved through using CGAs89.  
Overall, there is relatively little strong evidence about the impact of CGAs on cancer 
treatment decisions. For example, three systematic reviews looking at the usage of CGAs in 
oncology have concluded that the quality of studies on impact are generally poor to 
moderate90 and there has not been any randomised control trial examining the effectiveness 
of CGAs in changing treatment plans, or improving overall outcomes for older people with 
cancer. However, there are some promising findings about the impact of CGAs: 
- Several studies have found that CGAs often influence treatment decisions, however 
the proportion of decisions impacted is disputed91. One study conducted in 2013 
found that CGAs identified previously unknown issues in 51% of the study population, 
which resulted in changes to treatment decisions for 25% of patients and determined 
intervention plans for 26% of patients92. However, no follow up was done to 
understand the extent to which these decisions impacted eventual outcomes.  
- There is evidence to suggest that CGAs – and specific aspects of CGAs, such as frailty 
or performance status – have predictive value for chemotherapy toxicity93.  
Comprehensive geriatric assessment (CGA) is a multidimensional and usually 
interdisciplinary diagnostic process designed to determine a frail older person’s medical 
conditions, mental health, functional capacity and social circumstances. The purpose is 
to plan and carry out a holistic plan for treatment, rehabilitation, support and long term 
follow up. CGA is part of an integrated approach to assessment based on the following 
principles: 
• The older person is central to the process. 
• Their capacity to participate voluntarily must be assessed, and if lacking, then 
there needs be a system to address their needs in an ethical fashion. 
• Links between social and health care should be good enough for older people 
who need comprehensive assessment to receive it in a timely and efficient 
manner, and proportionate to their degree of need. 
• Assessments should be standardised and carried out to a reliable standard. 
• Circumstances which warrant a comprehensive assessment include, among 
others: 
o Acute illness associated with significant change in functional ability 
o Transfers of care for rehabilitation/re-enablement or continuing care 
o A frail patient prior to surgery or experiencing two or more “geriatric 
syndromes” of falls, delirium, incontinence or immobility. 
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- Kalsi et al concluded that older patients undergoing a CGA were more likely to 
complete chemotherapy, and fewer had changes made to their treatment plans, as 
interventions could be made that addressed a patient’s wider needs, for example 
managing existing conditions or providing additional medical or social support46. The 
authors recommended that ‘standard oncology care should shift towards modifying 
coexisting conditions to optimise chemotherapy outcomes for older people’. 
- Hamaker et al’s systematic review in 2012 found a link between CGA results and the 
likelihood of perioperative complications85.  
The Macmillan SCOPES project (Systematic Care for Older People in Elective Surgery) is a 
particularly interesting case study94. 
Although several organisations have produced guidelines on conducting CGAs in cancer3, the 
use of these is highly variable across countries and centres. This is often because of a lack of 
staff, as well as other institutional and/or funding constraints95.  
Furthermore, often the tools that are familiar to geriatricians are not used by oncologists, are 
not fit for the specific assessment of older people with cancer or are too long and 
                                                     
3 NCCN, SIOG, EUSOMA and EORTC 
Systematic Care for Older People in Elective Surgery (SCOPES) 
This project was developed at Nottingham University Hospitals NHS Trust in 2010 for lower 
limb joint replacement surgery, but was later extended to upper gastrointestinal cancer 
surgery.  
An outpatient clinic is held once a week, involving a range of health professionals – including 
geriatricians, specialist nurses, dieticians and social workers. A CGA is undertaken in one 
visit, with the results fed back to the upper GI cancer MDT. 
Patients can then receive additional support or clinical interventions to optimise their fitness 
before surgery. The SCOPES team can also help coordinate social care, either for the patient 
themselves or a loved one who is usually cared for by the patient. This approach has 
resulted in a number of positive results including reducing length of stay. 
… at the moment we’re looking at a reduction of approximately 28 days down to 16 
[in house calculations]now a lot of that will be ITU [Intensive Treatment Unit] care 
because the purpose of what we do is to optimise patients to get through whatever 
they’re having so if we’ve optimised them it means less time in terms of care or HDU 
[High Dependency Unit] which means less time in hospital because of building up 
their fitness we can get them home because we’ve got their packages organised for 
them they don’t have to wait on a ward blocking a bed. (SCOPES Project Manager) 
Recent evaluation – a prospective cohort study – aimed to examine the effect of the CGA on 
cancer MDT decision-making and clinical outcomes. This found that significantly more 
patients in the CGA group (33%) received potentially curative surgery than in the control 
group (18.2%). Six-month mortality was significantly lower in the control group (30.9% vs 
48.5%). Other outcomes were more consistent between CGA and control groups, for 
example palliative treatment decisions, post-operative length of stay and total use of acute 
care. This highlights how dietary, occupational therapy and physiotherapy reviews can 
directly contribute to treatment optimisation.  
Advancing Care, Advancing Years 25 
cumbersome to be used in everyday clinical practice96. Because of this lack of standardisation, 
O’Donovan et al. argue that ‘…geriatric assessment has yet to be optimally integrated into the 
field of oncology in most countries’97.  
This report will discuss the usage of CGAs in the assessment of older people with cancer 
across the UK, gathering views on their utility from health professionals. 
1.4.2 ASSESSING FRAILTY 
The British Geriatrics Society defines frailty as a long-term condition; a clinical state of 
vulnerability caused by decline of psychological and physical reserves98. 
Recognising and assessing frailty is an essential component of effective care for older people. 
Recent years have seen an increase in initiatives that aim to improve the quality of care by 
addressing the specific needs of people with frailty. For example, the British Geriatric society 
have worked with Age UK, the Royal College of General Practitioners and NHS England to 
provide best practice guidelines to manage frailty in the community (Fit for Frailty) and 
specialised quality checklists for people with frailty in acute settings (Frailsafe). 
Martin Vernon, National Director for Older People and Integrated Care at NHS England, has 
argued that frailty should be treated as any other long-term health condition99. This is in light 
of the increasing numbers of people with frailty and the systemic costs of ignoring the impact 
of this on hospital and community-based care. Vernon sees better identification, targeted 
assessment and individual care plans as the first steps towards averting a frailty crisis in 
health and social care. Frailty demands a whole system approach, with Vernon’s 
recommendation focusing on use of the electronic frailty index as standard for routine data in 
general practice.  
The Independent Cancer Taskforce also highlighted interactions between frailty and cancer, 
as well as the important role of frailty assessments and CGAs in informing treatment 
recommendations and identifying additional support needs. 
 
1.5 SHARED DECISION-MAKING  
The concept of shared decision-making (SDM) originated in the disability rights movement, 
expressed through the phrase ‘nothing about me, without me’. It has since played an 
increasing role in shaping health and care policy, both in the UK and internationally, with 
‘person-centred care’ more recently at the forefront of NHS England’s Five Year Forward 
View. The National Institute for Health and Care Excellence (NICE) have convened a Shared 
Decision-Making Collaborative, have published an action plan100 and have updated their 
processes for developing guidance so that shared decision-making is a key consideration. 
Despite this widespread support for the principle of shared decision-making, there is no 
universally agreed definition. For the purposes of this report we will use the definition 
adopted by the Health Foundation and NICE: 
‘a process in which clinicians and patients work together to select tests, treatments, 
management, or support packages, based on clinical evidence and patients’ informed 
preferences. It involves the provision of evidence-based information about options, 
outcomes and uncertainties, together with decision support counselling and systems 
for recording and implementing patients’ treatment preferences.’101  
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People who participate in decisions about their care are more likely to be satisfied with their 
care102. There is also strong evidence that SDM can improve patients’ self-efficacy, which can 
in turn have a significant impact on behaviours103. There is limited evidence that these 
improvements in self-efficacy can, in turn, impact quality of life and clinical outcomes. This is 
because individuals have care which fits better with their lifestyles104; more involvement in 
decision-making may also increase the chance that individuals adhere to their medication105.  
However, individual characteristics will affect how willing or able that person is to engage in 
SDM. For example, their attitudes, opinions and life experience, self-efficacy, activation and 
health literacy, socioeconomic and demographic status are all relevant factors. When people 
have low health literacy, self-efficacy or activation, they may lack the confidence, 
understanding or recognition to take an active role in decisions about their care106.  
Some older patients may face a particular set of challenges in engaging with SDM: they may 
be more likely to defer to authority, for example, to believe that clinicians should not be 
questioned, or think they lack the status to decide for themselves107. 
1.5.1 SHARED DECISION-MAKING IN CANCER  
SDM, particularly the use of decision aids, has been relatively prominent in cancer care 
compared to other conditions. This is partly because of the sheer number of decisions cancer 
patients are faced with throughout their diagnosis and treatment, from participating in 
screening through to treatment options.  
There is strong evidence that shared decision-making is beneficial to cancer patients. For 
example, the 2015 CanCORS study found that when patients report engaging in shared 
decisions they more often reported excellent quality care and good communication from 
their physicians. Importantly, this association held regardless of whether the individual stated 
an initial preference to make shared decisions108. 
There may also be variation by cancer site; for example there is evidence that patients with 
prostate and breast cancer are most likely to want to be involved in decisions compared to 
those with colorectal, gynaecological or lung cancers. However, the evidence on this is limited 
and cross-cut by other variables that might affect engagement – such as gender, age and 
disease severity109.   
1.5.2 SHARED DECISION-MAKING FOR OLDER PATIENTS  
Older people with cancer face a particular set of challenges which may make SDM more 
difficult. At the same time, these challenges make the principle of SDM ever more important. 
When cancer forms just one aspect of an older person’s multiple conditions, decisions 
become more complex and are not just based on clinical evidence110, 111,112.  For older people 
who are experiencing cognitive impairment, the different options can be challenging to 
understand and navigate.  
In the time-limited context of treatment decision-making, health professionals can perceive 
this struggle to engage in a conversation as a lack of competence113,114,115. The social and 
practical context of many older people’s lives can also add complexity to treatment decisions. 
In particular, isolation or caring commitments to others may limit older people’s engagement 
in their own treatment or present practical challenges116. 
Treatment decisions are also more likely to be more complex for older patients. Older people, 
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more so than younger people, may need to not only consider the potential benefits of a 
treatment option, but also consider their own life expectancy, and the effect of any of their 
other conditions. They must balance decisions about the quality of life they want to lead, 
against the length of time they want to live for. This is not only a highly complex medical 
problem, with an almost impossible to predict ‘right’ answer, but a challenging emotional 
decision117.  
This complexity is compounded by the fact that the evidence available to both health 
professions and patients on the potential impact and side effects of any treatment is 
significantly less than for younger people, partly a result of there being fewer older people, 
and people with comorbidities, in clinical trials118,119. 
1.5.3 THE ROLE OF FAMILY MEMBERS IN SHARED DECISION-MAKING 
Family members and carers often play a key role in providing care for people with cancer, 
particularly for older patients. When it works well, there is some evidence that sharing 
decisions leads to greater patient satisfaction, better treatment adherence, and allows family 
members to act as patient advocates, demanding the best care for their family member120,121.  
However, issues can arise where there are discordant views. This can be common, particularly 
when patients are older, caregivers are less educated and the patient-caregiver relationship is 
parent-child rather than spouse-patient122. Qualitative research suggests that this can be 
particularly difficult when decisions must be made about switching from curative to palliative 
treatment: family members can be less willing to stop active treatment, even when it causes 
severe side-effects. Patients themselves are often readier to accept and recognise that they 
are seriously ill than family members are123. 
1.5.4 THE ROLE OF HEALTH PROFESSIONALS IN SHARED DECISION-
MAKING 
The behaviours and attitudes of health professionals have a significant impact on patients’ 
ability to engage in SDM. As such, health professional training is the key to implementing 
SDM: it can overcome barriers to engaging with health professionals, for example any falsely 
held beliefs that they already work in a person-centred way or beliefs on the value and ‘cost’ 
of ensuring SDM.  
Health professionals often underestimate how much patients want to be involved in decisions 
about their care and make assumptions about their skills or ability to do so. For example, one 
study found that health professionals thought patients were far more likely to not take part in 
bowel cancer screening than they actually were124.  
Similarly, health professionals may assume that certain groups of older patients are less able 
to engage in decisions125. This is problematic, as there is often significant variation within 
groups126. Secondly, as previously noted, individuals may appear unwilling to engage in SDM 
but this may be because they can’t, rather than they won’t127 – and therefore health 
professionals should try and support patients to participate in SDM, where possible.    
1.5.5 THE ROLE OF THE HEALTH SERVICE IN SHARED DECISION-
MAKING 
A range of organisational and systemic factors affect the availability and impact of SDM. 
These include senior support and commitment, alignment with wider agendas, IT systems and 
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support capacity, and supportive commissioning and payment systems. If these factors are in 
place, the system has minimal barriers to SDM and includes incentives that encourage 
patients and clinicians to take part.  
Underlying this, there must be sufficient time and integration to allow meaningful SDM. A 
lack of integration between health services can be a further barrier to SDM, and particularly 
in cancer where individuals are increasingly living long-term, with and beyond cancer. For 
these people, care shifts between primary, secondary, community and social care – and 
information all too often does not flow between those services. If there are breaks in care, 
patients can feel ignored, demeaned and insulted128.  
A lack of time is also a common barrier to ensuring SDM; clinicians often perceive SDM as 
more time-consuming than ‘usual’ care, and there is some evidence that this is true. This 
makes health professionals less willing to use SDM, particularly when the time available for 
consultations is short. Patients also report that short consultation times limit their ability to 
be informed, to reflect on the information received and to ask questions. This is felt 
particularly acutely in the context of current pressures on cancer services: patients are 
sensitive to clinicians’ high workloads and are conscious not to ‘take up their time’129. These 
pressures particularly affect older patients, who are more likely to require more time to 
process information and think through options.  
   
1.6 THE POLICY LANDSCAPE 
All UK nations recognise that cancer is predominantly a disease of older age and that the 
ageing population prevents future challenges to the health service. However, given that 
health is a devolved issue, each nation takes a different approach to tackling the specific 
challenges of older people with cancer. 
1.6.1 ENGLAND 
The 2015 Cancer Strategy for England, ‘Achieving World-Class Cancer Outcomes: a strategy 
for cancer’, gives the most explicit attention to older people with cancer130. The strategy 
highlights that current assessment methods are not fit for purpose, which can result in older 
people’s needs not being identified or sufficiently well-understood. It also highlights the role 
of specialist geriatricians in orthopaedics as a positive example, transforming the approach to 
hip fractures, and identifies that there may be similar opportunities in cancer. The strategy 
makes two recommendations targeted towards older people with cancer: 
Recommendation 41: NHS England, the Trust Development Authority and Monitor 
should pilot a comprehensive care pathway for older patients (aged 75 and over in 
the first instance). This pathway should incorporate an initial electronic health needs 
assessment, followed by a frailty assessment, and then a more comprehensive 
geriatric needs assessment if appropriate. The pilot should evaluate a model in 
which the outputs of these assessments are considered by the MDT in the presence 
of a geriatrician, who would advise on AHP needs, co-morbidities etc., and their 
implications for treatment and emotional and physical support.  
Recommendation 42: NHS England should ask NIHR and research charities to 
develop research protocols which enable a better understanding of how outcomes 
for older people could be improved.  
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The National Cancer Information Network (NCIN) has also investigated the specific 
characteristics of older people with cancer; the key messages from their 2015 report have 
underpinned this report131. The report surmises that assessments are the key to ensuring that 
older people are offered the best treatment and that they are not excluded on the basis of 
age alone. The importance of evidence-based, systematic mechanisms of formulating 
treatment recommendations is central when acting to avoid treatment decisions being made 
solely on age, with implicit assumptions of frailty. Effective prevention, earlier diagnosis, 
enhanced support (especially in the community) and increased involvement in research are 
seen as other major priorities for improving older people’s outcomes. 
More broadly, NHS England’s Five Year Forward View, published in 2014, also focuses on 
older people132. This has translated into setting a research priority for understanding 
outcomes for older people with cancer, and piloting a comprehensive care pathway for older 
patients. 
1.6.2 SCOTLAND 
The most recent cancer strategy in Scotland is ‘Beating cancer: ambition and action’, 
published in 2016133. The strategy highlights the increasing number of older people and the 
(related) growth in long-term conditions, drawing attention to necessary improvements in 
prevention and diagnosis to mitigate increased demands on services. Engagement with 
people of all ages is described as key to spreading awareness of cancer symptoms and 
ultimately improving detection of cancer in the older population134, however there is no 
specific section on the treatment and care of older patients. 
1.6.2 WALES 
The Cancer Delivery Plan for Wales, published in 2016, focuses on inequalities within the 
older population135. Tackling health inequalities are seen as a priority for Welsh health policy, 
strategy and governance. Solutions focus on the importance of localised approaches and 
involvement of partners in public health and the third sector, however there is no specific 
focus on older people with cancer. 
 
1.6.2 NORTHERN IRELAND 
Northern Ireland does not currently have a cancer strategy and so it is difficult to ascertain 
the extent to which there is a strategic focus on the needs of older people with cancer. 
However, we do know that there is a particular interest in rural isolation and the related 
transport issues. The Northern Ireland Assembly cancer services research and information 
briefings directly challenge the consequences of service centralisation on these grounds136. 
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2 OLDER PATIENTS HAVE MORE 
COMPLEX CARE NEEDS – AND 
THE SYSTEM IS NOT SET UP TO 
DEAL WITH THEM 
Older people with cancer are more likely to have complex medical and social needs, and 
therefore may require additional support to access treatment. For example, older patients 
are more likely to have other age-related illnesses, but also more likely to require social care 
support. These factors make it ever more important to ensure that decision-making is shaped 
around each individual patient’s circumstances – and more could be done to ensure that this 
is always the case.  
2.1 CLINICAL FACTORS 
Older people have an increased prevalence of age-related comorbidities such as diabetes, 
hypotension, atherosclerotic disease, chronic respiratory disease, arthritis and cognitive 
issues137. Cognitive issues can pose a particular challenge; up to 40% of older patients present 
with cognitive issues that impair their capacity to make complex decisions about treatment, 
adhere to treatment plans and recognise symptoms of toxicity that might require medical 
attention138.  
These factors combined lead to difficult decisions for clinicians forming treatment plans for 
older patients. As well as treatment efficacy, clinicians must also consider the impact of a 
treatment regime on the patient’s quality of life and their likelihood to adhere to a treatment 
regimen, interactions with multiple comorbidities and the likelihood of the patient’s condition 
deteriorating during treatment because of a pre-existing condition.  
Our thematic analysis of all survey and case study material, aside from responses from 
primary care, has identified four main clinical factors which would determine what treatment 
an older patient may receive: 
1. The patient’s fitness to withstand the rigours of treatment;  
2. The likelihood that the patient will die from a cause other than their cancer;  
3. Whether the patient has co-morbidities;  
4. If there is clinical evidence to support a particular course of treatment in an older 
patient  
2.1.1 PATIENT FITNESS 
Where clinicians are concerned about a person’s fitness to withstand treatment, they will 
often work with the patient to optimise their treatment options – often referred to as “pre-
habilitation”. For example, they might focus on improving the person’s fitness before surgery, 
or they could start with a lower dose of chemotherapy to check how the person responds to 
toxicity. However, interviewees recognised that this could require older patients to undergo 
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more investigations to check their fitness. This can be challenging to do while still meeting 
national targets, as these interventions take more time. This has been echoed in research, 
which has found that service targets that focus resource solely on cancer can disadvantage 
patients with complex wider needs, as individual clinicians may struggle to deliver effective 
treatment plans without breaching targets139. 
This is particularly relevant for older people with lung cancer, who often have particularly 
complex needs: many are elderly and can have related comorbidities such as cardiovascular 
disease, vascular disease, Chronic Obstructive Pulmonary Disease (COPD) and lung disease 
(from smoking). In this case, even if the individual has a curable cancer, their treatment 
options can be limited since the patient is simply too unwell to cope with extensive diagnostic 
tests and treatment. 
We have a lot of patients that can’t get through tests, because you know they’ve had 
bleeding issues from their cancer or they’ve got poor lung function test [results], they 
can’t do a needle biopsy. Or they bled at bronchoscopy … Or they have a stair test and 
they only manage two flights. … Or they’ve got lung fibrosis so I can’t give them 
radiation of a curative type. (Clinical oncologist) 
The physical mobility of a patient can also limit options, including in terms of diagnostic tests.  
 So if a patient is unable to elevate their arm that means they wouldn’t be able to have 
radiotherapy … if I can’t elevate their arm the chances are I won’t formally assess the 
axilla [armpit]. (Radiologist) 
However, clinicians also reported working around these limitations to provide the best 
possible care in the circumstances. 
 …we can’t work them up as well as we would somebody younger because they’re not 
physically fit enough to have mammograms say, but I will often and my colleagues will 
often do a biopsy with them say sitting in their wheelchair so that we can get the 
hormone receptive status and treatment with chemotherapeutic agents such as 
Tamoxifen, without the need for more invasive tests. (Radiologist) 
A number of interviewees from case study sites with a particularly elderly demographic 
mentioned their experiences of having ‘pushed the boundaries’ of what might be considered 
‘usual practice’ when it comes to older patients, with the driver for this being the need to 
maintain comparable treatment figures to other areas.   
 And we have had some situations, elderly patients, where they’re not fit enough for a 
general [anaesthetic]. We wouldn’t do an auxiliary clearance for example under a local, but 
we have done  mastectomies and wide local excisions under local anaesthetic.  (Cancer Nurse 
Specialist) 
Anaesthetists can make a significant contribution towards optimising a patient’s options for 
treatment and those interviewed for the study reported drawing on a range of resources and 
expertise to facilitate this. This might involve a referral back to the patient’s GP to optimise 
someone’s inhaler use, or the administration of iron pre-operatively, or asking cardiologists to 
adjust someone’s medication to improve cardiac output.  
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2.1.2 COMORBIDITIES AND POLYPHARMACY 
Older people with cancer are more likely to have other pre-existing health conditions. As well 
as implicating a potential treatment plan, this also means that they are more likely to die 
from something other than their cancer compared to younger patients140. This can complicate 
treatment decision-making, since side-effects of cancer treatment could have a significant 
negative effect– as highlighted by an interviewee for this research. 
 In elderly patients with small renal masses we are … more likely to adopt a 
conservative approach where we will monitor the growth of that tumour before making a 
decision to treat, because if it turns out to be essentially sessile tumour mass that is not 
growing, then that patient is probably never going to run into bother with that tumour for the 
remainder of their natural life expectancy. (Medical oncologist) 
It can also be difficult to control for possible interactions between multiple medications, 
which is known as polypharmacy. Patients and clinicians can be faced with a trade-off 
between maintaining a drug regime that controls their other conditions and possibly 
disrupting that to receive cancer treatments. This can be the case for both mental health 
conditions and physical health conditions. 
2.1.3 CLINICAL EVIDENCE 
As will be discussed further in section 6, there is often relatively limited evidence to support 
the use of new treatments in an older population, since older patients are under-represented 
in clinical trials.  
This is an important issue: as well as being more likely to have comorbidities and to be on 
other medication, older patients can also have biological differences that can impact 
treatment efficacy. A person’s chronological age can have a significant effect on their 
response to medication. For example, age-related changes in liver, kidney and gut function 
significantly impact how drugs are absorbed, distributed around the body, metabolised and 
excreted141.  
2.2 SOCIAL FACTORS 
Social factors can have a significant effect on how people view their own health and 
treatment options, particularly if patients must travel a significant distance to receive their 
treatment.   
This research has highlighted a range of potential barriers to older people accessing 
treatment or to making a decision that is right for them. Some barriers relate to practical 
issues, whereas others concern attitudes or beliefs. It was also noted that the extent to which 
these barriers could be removed varies significantly.  
2.2.1 COGNITIVE IMPAIRMENT 
Healthcare professionals find that treatment discussions are particularly challenging when 
patients have cognitive impairments. Clinicians are often reliant on the patient’s own 
assessment of their abilities, which may be inaccurate. Patients may also overestimate their 
activity levels, perhaps from a sense of denial of physical decline, or from a desire to convince 
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the clinician that they are fit for surgery. In these instances, the involvement of family 
members or carers is often critical. 
 
Dementia affects 810,000 adults over 65 in the UK and just 40,000 people under the age of 
65142. Dementia has a huge impact on decision-making in general, but particularly on securing 
patient consent for treatment, since memory problems can impact a patient’s ability to retain 
information and make an informed decision. If an individual has significant mental 
impairments and is unable to understand the options outlined to them, pursuing active or 
‘conventional’ treatment options can be difficult. This is partly because patients may be 
unable to recognise negative side-effects or complications of treatment.  
 
However, through our interviews we heard some doubt about how it can be difficult to 
identify patients with dementia if they do not yet have a formal diagnosis and the progression 
of their disease is mild. Furthermore, it is unclear how patients with more severe dementia 
are identified and flagged to the MDT managing their care – as will be discussed later in this 
report.  
 
Other cognitive issues can also have an impact on treatments. For example, older patients 
who have suffered a stroke or other brain injury may have difficulty retaining information and 
making complex decisions. This gives further weight to the case for  more widely used robust 
tools that can factor these issues into decision-making in a consistent way. 
2.2.2 SOCIAL SUPPORT NEEDS 
For many older people with cancer, their wider social situation has a significant impact on 
treatment decisions. For example, patients may have caring responsibilities or may 
themselves need additional social support. A lack of family or carer support can be a concern 
for clinicians making recommendations, since it can increase the patient’s risk of post-
treatment complications and make it harder to pursue active, ongoing treatment. This is 
particularly the case for chemotherapy. 
 I use chemotherapy to treat cancers and one of the important criteria is to the ability 
to be supported and the ability to seek help if there is any adverse events or toxicities… the 
patient needs to be… clued in to seek help and… we know people cope well if they are 
supported from the family and given the density of some of the chemotherapy, I do take a very 
cautious view if the patient does not have any adequate social family support. (Medical 
oncologist) 
46% of MDT members surveyed for this research identified the lack of social or practical 
support as a barrier to older people accessing the most effective treatment for their cancer. 
This was echoed by patients involved in the study, who felt strongly that a lack of certainty 
about how they will access non-medical support was a significant barrier to accessing 
treatment. This fear was often heightened by public reports of financial pressures on the 
wider health and care system. 
It’s one thing to choose to decline treatment, because the effort of chemotherapy and 
how ill it’s going to make you feel isn’t worth (it)…  It’s very different to making a 
decision based on ‘I can’t get the care for my husband or I can’t get the care for my 
wife or I don’t have transport to get to the chemotherapy … Or I’ll feel too rubbish 
afterwards and there’s nobody around to do my cooking and cleaning’…. (National 
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interviewee) 
Reassurance of domiciliary care, adaptations and devices, self-care advice (physiotherapy and 
diet), carer benefits and respite were described as factors that might have an impact in 
treatment decision-making, where these needs are identified and addressed early on. 
The reality of older patients turning down treatment because it would mean they were 
unable to fulfil their caring responsibilities was a recurring theme from health professionals 
and patients involved in this study. 
 
Many older people care for someone who is dependent on them and such responsibilities are 
more likely to cause difficulties for older patients than younger ones. These issues are 
particularly prevalent amongst patients whose treatment is long-term and debilitating. This 
can have a significant effect on how people view their own health and treatment options.  
…his wife has severe dementia, he was her main carer, … And I said to him ‘you know 
we can do this surgery, we can cut the tumour out, but I don’t think you’ll get out of 
hospital for three to six months, you need to be aware of that’, and he said ‘well I can’t 
do that, because I need to care for my wife, and she’s deteriorating.’ (Anaesthetist) 
 …. And that’s quite a common barrier to treatment actually, because the patient will 
say, you know, I don’t want to compromise my own health because if my own health is 
 compromised, I may not be able to continue looking after my spouse. (Medical 
oncologist) 
Though it is possible for alternative care to be arranged so that people can receive treatment 
and recover, for many people this will be a logistical and emotional struggle at a time when 
they are likely to be feeling unwell and vulnerable. These concerns and fears can be 
exacerbated if the person being cared for has dementia or other cognitive decline, as this can 
often increase anxieties about how they will cope with a change in circumstances.  
Furthermore, there can often be a significant cost associated with arranging alternative care, 
as well as logistical difficulties143. Although some may be eligible for financial assistance, many 
are not. These considerations might mean that patients delay or discount treatment 
altogether but it might also lead to unrealistic expectations of how people might cope with 
recovery and caring for a dependent spouse or partner.  
 I think sometimes people don’t know how big the operation is … and I don’t always 
think they’re fully aware of what the implications may be … they might think if I’m out of 
hospital after a week I’m going back to looking after my wife …. (Anaesthetist) 
In these cases, the role of community-based oncology nurses is vital, as are flexible models of 
delivering treatment such as community- or home-based chemotherapy. However, the range 
of services available ranges considerably across the country. 
…in some parts … we’ve got very good support by community oncology nurses so they 
see patients who are having chemotherapy and can give some chemotherapy at home 
as well and monitor their side effects but in some other areas … that service isn’t 
available …the palliative care services are available across [the region] but again the 
palliative care occupational therapy services in some areas aren’t available for some 
patients. (Cancer Nurse Specialist) 
For surgery, the support available to a recovering patient is important, however did not seem 
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to limit whether a patient was offered a particular course of treatment.  
 I don’t know if I’d ever deny anybody an operation if they haven’t got family support if 
everything else was kind of in the balance… I think it’s a good thing if they’ve got it but 
I don’t think I’d hold it against them or weigh it against them if they haven’t … 
(Anaesthetist) 
In some cases, hospital-based care can be extended to ensure that the patient is recovered to 
a point that they will be able to cope at home. In other cases, patients can be referred to 
rehabilitation or convalescence homes. Unfortunately, there are significant bed shortages at 
these facilities and so this is often not an option.  
Wider issues with the social care system also have a significant knock-on effect on cancer 
care. National interviewees and two social workers linked to oncology teams highlighted that 
the social care assessment process is limited by it being too reactive, meaning patients must 
wait until after treatment for an assessment to be made.  
 We can fully anticipate that after major surgery or a period of chemotherapy someone 
is going to be in a state to need the care. So why can we not plan to put it in and cancel it 
 when we no longer need it? And I think I know what the answer to that is and that’s 
about the fact that we don’t have enough resources to cope with what we’ve already got. 
(National interviewee) 
2.2.3 TRAVEL REQUIREMENTS 
Some patients will be required to travel some distance to access treatment that is more 
specialised. For example, interviewees at a Northern Irish site spoke of their patients being 
sent to Leeds for stereotactic radiotherapy until a local service was established. But even for 
more routine treatment, frequency and inconvenience of travel can be a barrier to access.  
 …depending what treatment they have that can be quite an intense scanning regime 
 certain types of treatment in the first year requires for you to have four MRI scans 
which are not the most pleasant things in the world so there can be a lot of travel involved.  
(Urologist) 
This is a particular issue for radiotherapy, which requires regular attendance, often over 
several weeks. Though this impacts patients of all ages, older and more socially 
disadvantaged people are more likely to be reliant on public transport or lifts from friends 
and family when they access public services144.  
These issues have clear implications for treatment options. For example, clinicians and 
patients with breast cancer may opt for a mastectomy where there is concern about the 
ability to manage the daily travel requirements for radiotherapy following local excision 
surgery.  
 All our patients who have wide local surgery are offered radiotherapy and if they're 
really too ill to come up and down to the hospital, …patients who really can’t cope with 
radiotherapy after breast cancer surgery, we fully recommend the mastectomy, because then 
there is no risk to the rest of the breast. (Radiologist) 
Transport issues are most problematic for tertiary centres which serve a mainly rural area. 
These issues are then compounded when treatment (and monitoring) requires frequent 
hospital visits, with minimal scope for remote or community-based support.   
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 Obviously we work with local hospitals and community care to manage toxicities and 
 complications of the disease and the like, but we have no alternative but to see them 
here. (Medical oncologist) 
Interviewees based at sites where patients are more likely to travel expressed concerns that 
this could exclude frailer or older individuals from treatment. This was also raised as a key 
barrier to taking part in clinical trials.  
So yes, it is more difficult for older people to get transport and it’s possible that a lot of 
them don't want to be a bother to their families …getting on buses, trains, whatever, is 
not ideal and the kind of ambulance, minibus service trails them round the country so 
they don't like that … it’s another burden that they have. (Medical oncologist) 
In England, where radiotherapy services are soon to be re-organised into new Radiotherapy 
Networks, there is a timely opportunity to embed the needs of older people with cancer in 
this process, through meaningful patient involvement as services are planned. 
 
Recommendation: UK health services should ensure that the specific needs of older patients 
are considered in all new service plans and workforce plans. For example, emerging 
Radiotherapy Networks in England should consider the impact of changing travel 
requirements on older patients and should work with charities and providers to ensure all 
patients are given the support they need to receive treatment. 
2.2.4 FINANCIAL ISSUES 
The cost of being ill can be significant. For older people, this cost often relates to the need to 
fund care for dependents while the caregiver is receiving treatment, as discussed above. 
Beyond this, there can also be a financial cost of paying for support for the patient 
themselves, including home care, residential nursing care or more general social care support. 
Interviewees highlighted that this is often poorly understood by patients and their families. 
 What I find very strange …is when people come into hospital and we discharge them 
with a care package they do not know how much it’s going to cost. …I’ve never 
understood why nobody ever challenges that … nobody asks how much it’s going to be 
and there’s no way of us being able to tell them either…  (Oncological social worker) 
Recommendation: Cancer service managers should ensure that patients’ support needs are 
assessed at an early stage in the pathway, so that they are able to access the support they 
need during and after completing treatment. Health service regulators should consider 
ways to ensure that this is done effectively and consistently across the UK. 
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3 TREATMENT DECISION-MAKING 
DOES NOT ALWAYS TAKE ALL 
RELEVANT FACTORS INTO 
ACCOUNT 
We can only be sure that treatment decisions are right for patients if we are confident that 
decisions have been made with consideration of all relevant information about that patient. 
This is true for every patient, but is most important for patients with additional medical and 
social needs – and so often very important for older patients.  
Unfortunately, these complex needs are often not routinely considered as part of the 
treatment decision-making process in cancer. This is partly because services lack the right 
tools to assess frailty in the cancer setting, and Comprehensive Geriatric Assessments are still 
rarely used in oncology. This is important: it is widely recognised that chronological age alone 
is not a strong indicator of how well a person will tolerate cancer treatment145. 
Unfortunately, these complex needs are often not routinely considered as part of the 
treatment decision-making process in cancer. This is particularly true for frailty assessments – 
which can have a significant impact on how likely a person is to tolerate treatment. In the 
absence of a robust method, assessment of a patient’s fitness for treatment can be assumed 
based on their chronological age, or how they seem during a consultation. One reason for 
this, as outlined in the most recent Cancer Strategy for England, is that standardised 
assessment tools – such as a CGA – are rarely used. 
A CGA supports clinicians making difficult treatment decisions for older people, by reducing 
the subjectivity of the decision-making process. More specifically, a CGA can support a 
clinician to understand a patient’s likely tolerance of treatment and the impact of 
comorbidities on their outcomes, allowing them to alter treatment and care plans accordingly 
– and in a systematic, evidence-based way.  
3.1 THE USE OF COMPREHENSIVE GERIATRIC 
ASSESSMENTS IN PRIMARY CARE 
In our survey of primary care staff, 70% of respondents told us that their assessment of an 
older person’s frailty influenced their decisions to refer patients for diagnostic tests or 
treatment. However, the use of standardised, evidence-based assessment tools to measure 
frailty objectively was limited. Instead, GPs and other primary care staff tended to rely on 
clinical assessments, patient history and physical examinations to assess frailty (Figure 4). 
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FIGURE 4: PRIMARY CARE STAFF’S METHODOLOGY FOR ASSESSING FRAILTY  
 
When exploring this further in national interviews and local interviews with GPs and GP cancer 
leads, interviewees indicated that GPs might not be very aware of standardised tools and 
guidelines around assessing frailty, or the evidence supporting their use.  
I think very few (in primary care) are using sort of formal frailty indexes or quality of 
life indexes or even functional assessments. (National interviewee) 
I have to admit I do know the seven-point score that’s come in quite recently but I’ve 
never used any specific scale to assess anyone’s frailty. I don’t know what the evidence 
is behind that frailty score, so I guess that’s important. (General Practitioner) 
However, there are some local tools which are being used, for example the validated 
electronic frailty index (eFI) developed by academics from the Yorkshire and Humber 
Collaboration for Leadership in Applied Health Research and Care (CLAHRC). This index uses 
existing electronic health record data to identify and grade frailty, then identifies the top 2% 
most vulnerable patients for targeted care planning146.  
The eFI is now available to GPs in electronic health record systems that cover 90% of the UK 
population and has been included in NICE multimorbidity guidance147. The developers have 
recognised that its use in primary care could result in improvements in secondary care and 
specialist services, including cancer148. However, we also know that communicating such 
information to secondary care can be challenging.  
3.2 THE USE OF COMPREHENSIVE GERIATRIC 
ASSESSMENTS IN SECONDARY CARE 
Interviews conducted for this study revealed that, while there are some champions, the 
perception of many acute clinicians is that few appropriate tools currently exist and where 
they do, the value they might add to the decision-making process still needs to be proven. 
This finding aligns with the literature: there is currently no standardised method for 
conducting comprehensive geriatric assessments, and there is no agreement on the most 
effective measurement tools or the impact the use of certain tools might have on both 
treatment decisions and treatment outcomes.   
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It was also suggested by one or two acute clinicians interviewed for this research that more 
formal assessment tools should not get in the way of the more informal assessments such as 
‘just seeing how a patient walks into the consultation’. 
 While CGA, frailty assessment etc. might sound more technological, I think in reality 
they would add extra workload and would not improve on the end of bed assessment that 
someone is fit for intensive treatment or better on less intensive treatment. (Surgeon) 
Using a general notion of frailty to assess fitness for treatment was common practice in 
secondary care, however participants found the objective measurement of this concept 
challenging – preferring a more intuitive approach.  
Some secondary care interviewees mentioned the use of a handgrip test to determine 
strength and the sitting and standing test but appeared in practice to accept a far more 
intuitive sense of underlying status among older patients, while recognising there are 
limitations with this approach. However, there are some tools being used. 
3.3 WHAT ASSESSMENT TOOLS ARE BEING USED? 
3.3.1 CARDIAC AND RESPIRATORY FUNCTION TESTS 
Acute secondary care team members suggested that cardiac and respiratory function tests 
were the most significant indications of fitness for surgery. ECGs are often used to assess 
cardiac function, to identify irregularities such as atrial fibrillation – which would be a red flag 
indicating that the patient would be unable to tolerate a general anaesthetic.  
CPET or CPEX149 testing is considered the gold standard for testing cardiorespiratory function, 
however it requires specialist equipment, facilities and staff resource – which may not always 
be available. This testing also requires cycling activity, which many patients may be unable to 
complete. Instead, study participants spoke of a more informal assessment, in which they 
ascertain patients’ ability to undertake various activities of daily living (ADL).  
 So I ask about their activities of daily living what they can do for themselves and then 
in terms of exercise my first question is if they can climb two flights of stairs we kind of get a 
 rough guide of metabolic equivalents …so if they can climb two flights of stairs that 
means  they can usually raise it four fold which in the literature is considered adequate for 
major surgery when they have abdominal surgery. (Anaesthetist) 
3.3.2 PERFORMANCE STATUS 
Performance status is a World Health Organisation definition describing how mobile a person 
is, from a scale of 0 to 5 – with 0 being someone who is fully active and able to carry on all 
pre-disease performance without restriction. However, some clinician interviewees 
recognised that this is not often detailed enough to inform treatment decisions since it does 
not take important biological factors into account.  
…the age of the patient is an important factor… I’ve treated elderly people with 
systemic treatment and they are performance status one, but these people have older 
kidneys, old livers and the drugs that they’re getting are processed and metabolised 
often through one or either both of those organs. And you’re getting people with older 
body organs and you’re giving them toxic drugs which already have a risk of death. 
(Clinical oncologist) 
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Decisions can be particularly difficult when individuals are functionally fit and perceive 
themselves to be very fit, but have other health conditions that would jeopardise the success 
and safety of systemic treatment. One particularly striking example was given of a patient 
who was physically very fit and active but had stage three kidney disease and a weak heart 
from a previous heart attack. 
For me, that was a very difficult conversation to have because he looked so well and he 
looked fit …but I've seen what one cycle of chemotherapy can do with someone whose 
kidney function is already extremely borderline, I've seen it put people into complete 
renal failure. I've seen it trigger another heart attack … (Cancer Nurse Specialist) 
This quote demonstrates the value of a more complete frailty assessment that includes 
medical history as well as functional testing – and that this is particularly pertinent for 
decisions about chemotherapy. 
3.3.3 RISK SCORE ASSESSMENT 
Clinician interviewees saw information on risk scores as helpful, particularly in terms of 
providing information to patients so that they can be involved in decision-making. Risk scores 
provide an average score for a person of a specific age, without comorbidities or underlying 
conditions, which can be compared against a risk score for the same patient with specific 
comorbidities or underlying conditions. These are widely used, for example POSSUM 
(Physiological and Operative Severity Score for the enUmeration of Mortality and 
Morbidity150). 
However, these tools also have limitations. One interviewee noted that these risk scores are 
based on measuring the average performance of US centres undertaking these procedures 
but may not have the same applicability in a UK context. 
 …again (it’s) done in big numbers but it’s still done in America there’s a lot of variation 
from centre to centre. As a big centre we are probably better than some of the 
American centres … you expect that it will average out but if you are one of the well 
performing Trusts your numbers could be better than that, or if you’re not so well 
performing your numbers could be worse than that …  (Anaesthetist) 
3.3.4 HOLISTIC NEEDS ASSESSMENT 
A Holistic Needs Assessment (HNA) is a wide-ranging assessment that considers physical and 
practical concerns, as well as the patient’s emotional and information needs. This is often 
linked to the development of a care plan that takes these factors into account. 
At one site involved in this research, patients with breast cancer have an hour-long 1:1 pre-
operative discussion with a breast care nurse that includes an HNA. 
 We find out about them, when they worked, what their life was when they were in 
employment, what life experiences they’ve had. Whether they’ve had any experience 
of cancer, what their family situation, what their home situation is. Finances as 
well…and we also do our hospital anxiety and depression score as well. (Cancer Nurse 
Specialist) 
While HNAs have significant merit, they are relatively resource-intensive and interviewees 
reported that a lack of time and capacity limits their use.  
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3.3.5 SUMMARY 
Only one case study site systematically used any form of CGA and in general we found very 
low usage of validated assessment tools. This is particularly concerning when considering that 
‘frailty’ was highlighted as the most influential factors in clinical decision-making in the survey 
of MDT members (at 79%). Many clinicians interviewed perceived there to be very few 
appropriate tools and were unconvinced of the value such tools would add to the decision-
making process.  
Overall, despite several concerns raised as to the variability in how clinicians in acute settings 
might assess a person’s frailty, we found that validated tools were not widely used in 
assessing older patients and there was no evidence of the systematic use of any form of 
comprehensive geriatric assessment in the acute sector – as is echoed in academic literature 
and in 2012 research by Macmillan Cancer Support151.  
We heard concerns amongst some national interviewees that the use of subjective 
assessments of frailty could result in inequalities in access to treatment for older people with 
cancer. 
I mean certainly the data would suggest it (primary care frailty assessment) may be 
part of the problem. If you look at the sort of the cancer outcomes and sort of stages at 
presentation, clearly there is a bias and we are serving our elderly patients less well 
than we are their younger compatriots. There will be both patient factors and 
professional factors. And it’s almost what I would call a medical societal issue and it’s 
sort of along the lines if we want to address it we will have to address both sides of 
that equation. (National interviewee) 
Our interviews also highlighted that people living in care homes could be particularly at risk of 
being overlooked for potential treatment. In this instance it is possible that, in the absence of 
any systematic method of assessment, frailty is simply assumed and overestimated, leading to 
a lack of referral.  
wonder whether they (primary care) investigate patients in nursing homes as much 
as they would if they weren’t in a nursing home – there may be a degree assumption 
going on ‘I don’t think Mrs Bloggs is well enough’ and I wonder whether there is a 
better way of working with GPs to assess performance status. (Medical oncologist) 
It is clear from this research that the clinical community has concerns about some older 
people not being assessed objectively. However, there is also a relative lack of evidence about 
the most appropriate formal tools and protocols. Several attempts have been made to 
recommend best tools, however no standardised method has been agreed.  
The UK Macmillan Cancer Support and Department of Health Older Persons Pilot 
demonstrated that geriatrician liaison was the most effective way of delivering CGA. 
However, Kalsi et al have suggested that CGAs could be undertaken by nurses or other 
clinicians, if facilitated remotely by a geriatrician. This is likely to be more manageable for the 
health service at present, given the current workforce shortages.  
Recommendation: NHS England and devolved health services should undertake further 
research to understand the most appropriate form of CGA for older people with cancer and 
should pilot their wider usage.  
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4 THE RIGHT INFORMATION DOES 
NOT ALWAYS GET TO THE 
RIGHT PEOPLE TO SUPPORT 
CLINICAL DECISION-MAKING 
The information about a patient that is available to the clinician involved in making treatment 
decisions is highly variable. It depends on the referral route, the pathway the patient is 
following and the stage of the pathway they are currently at. So, for example, the information 
available for decisions to be made will be quite different if a patient is seen as: an emergency 
in A&E; as a result of a two-week urgent referral from their GP; following referral from a local 
hospital to a tertiary centre; or if they are on a follow-up pathway, having previously received 
treatment.  
 
There are several key points of focus where the transfer of information is particularly 
important: between primary and secondary care, and to and from the multidisciplinary team 
(MDT). 
4.1 INCLUDING THE RIGHT INFORMATION FROM 
PRIMARY CARE 
Primary care clinicians often have the most detailed history of a patient, including their level 
of frailty and any comorbidities. However, this information can only be factored into cancer 
treatment decision-making if it has been passed from primary care to secondary care. 
Unfortunately, we heard from both primary and secondary care interviewees that they often 
find it difficult to get in touch with each other directly. 
We tested the idea of increasing the involvement of primary care in pre-treatment 
optimisation. While primary care respondents to our survey wanted to support older people 
with cancer, and saw value in using GPs’ knowledge, there was widespread concern over their 
capacity to do this. 45% of respondents said that they did not know if they would like to see a 
greater role for primary care in pre-treatment optimisation, which is likely due to the tension 
between what is desirable and what is realistic in the current resource context. 
The challenge at this moment in time is that general practice is seeing its worst 
recruitment crisis that most GPs can remember and there is simply not the resource 
available to take on more work. There is not the capacity and locally, I see practices 
close. It’s not a lack of willingness, it’s just not being able to and I think with regards to 
improving services, it would need to be done in such a way that it is so time light, it just 
needs to be done in such a clever, easy, encouraging way, rather than just simply 
burdening GPs with more work. (General Practitioner) 
FIGURE 5 (PRIMARY CARE SURVEY) WOULD YOU LIKE TO SEE A GREATER ROLE FOR 
PRIMARY CARE IN PRE-TREATMENT OPTIMISATION?  
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4.1.1 THE TWO-WEEK WAIT REFERRAL FORM 
A major issue raised through the primary care survey, national and local interviews was the 
nature of the two-week wait referral form, which is used when patients are given an urgent 
referral for suspected cancer. 37% of patients in 2015 were diagnosed through this route in 
England152. These forms are brief and thus there is no space for primary care staff to 
communicate people’s personal circumstances, comorbidities, their frailty or other medical 
history. This means that the clinicians making decisions about patients’ treatment often do 
not have advanced access to information that could later prove critical – and so the person’s 
age is more likely to be used as a surrogate measure for their overall health. 
One of the biggest problems we have is that when we refer somebody from general 
practice with a suspected cancer diagnosis, we use this two-week referral pathway 
which involves a very basic one page form which essentially says “What’s the thing 
you’re referring them for and why?” Nothing else. It doesn’t say what medication 
they’re on, what are their co-morbidities, what are the real issues, what are the social 
factors, doesn’t tell anything about the person, it just tells you potentially what could 
be related to the disease. (National Interviewee) 
It is understandable that this form is brief: it is by nature urgent, and the vast majority of 
patients given an urgent referral do not go on to receive a cancer diagnosis. But for those who 
are then diagnosed with cancer, the clinician responsible for their future treatment has very 
limited information about their patient to factor into their decision-making. This was 
described as a waste of a ‘phenomenal resource’ by one national interviewee who is a GP.   
In the absence of a comprehensive overhaul of information systems to facilitate data-sharing 
between primary and secondary care, relatively simple changes to referral forms could result 
in a significant improvement in the amount of information available to inform treatment 
decisions. As forms differ from region to region there are some notable examples of good 
practice, where those making referrals have space for additional information. 
The GP below describes how important factors for treatment decisions can be overlooked, 
such as dementia. These types of situations can lead to reversed treatment decisions – which 
introduce avoidable delays that can be distressing to patients and caregivers, and ultimately 
lead to wasted time and resource. 
What might be really important is working out how to work efficiently, thinking about 
information flows. So if there would be, for example, on the two week wait referral 
form, those five areas of cognition… it would just be a simple tick box exercise to 
identify areas that the oncologist would need to take into account, because sometimes 
if a patient has been muddled a bit but nobody has taken the initiative to investigate, 
this patient could have undiagnosed dementia and [is] being referred by the two-week 
wait. (General Practitioner) 
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4.2 THE ROLE OF THE MDT 
Every patient diagnosed with cancer in the UK has their case discussed at a MDT meeting. An 
MDT is made up of a variety of health professionals involved in treating and caring for 
patients. The MDT meets, most often weekly, to discuss individual patients’ cases and make 
treatment recommendations.   
This meeting will often occur before the patient has met a secondary care clinician, meaning 
any information of frailty must be generated by the primary care team referring the patient. 
However, we know that means to transfer this information are limited. MDT members 
responding to our survey also expressed that they would like more information from primary 
care; specifically, other medications and comorbidities. 
Again, knowledge of frailty assessments within MDT members seemed largely weak. 
 Because there isn’t always a sole diagnostic test that you can say this person is frail - 
it’s often a constellation of things and you know we’re very good at picking up peoples’ 
comorbidities but how do you define someone as definitely frail I don’t think that’s 
taught particularly well in my opinion. (Anaesthetist) 
The purpose of the MDT discussion is to make a treatment recommendation; the final 
decision must then be made by the clinician and the patient. The MDT is an opportunity for a 
variety of health professionals to come together and share their expertise, to formulate the 
most appropriate recommendation for their patients. 
If MDTs are to make a treatment recommendation that is truly appropriate for the patient, 
they must include all relevant information. But recent research by CRUK found that only 14% 
of MDT discussions included information that did not specifically relate to the patient’s 
tumour153.  Whilst this is concerning for all patients, this is likely to disproportionately affect 
older patients as they are more likely to be comorbid and to have complex social needs that 
will impact treatment decisions. 
Furthermore, past research has found that between 10 and 15% of treatment 
recommendations were not implemented because they were too extreme for the patient154. 
It is likely that this is because the MDT did not take all relevant factors into account – for 
example comorbidities, frailty or the patient’s preferences.  
Whilst Clinical Nurse Specialists are considered to be most qualified to provide such 
information, nurses did not contribute information in over 75% of meetings observed during 
that research – perhaps as a result of a shortage of CNSs, as well as the marginalisation of 
nurses and other allied health professionals155. This reflects the lack of time available for full 
discussion of complex patients in MDT meetings: the average discussion observed in our past 
research lasted just 3.2 minutes, in meetings lasting up to five hours, and included an average 
of just three people – although an average of 14 people were in attendance.  
This pressure has major implications for the quality of treatment decision-making. Not 
including important information about a patient – such as their preference, their psychosocial 
situation or their comorbidities – is poor for patients and also poor for MDT efficiency. 
There is a clear need to reform and streamline MDTs, so that more time is available to discuss 
the most complex patients in enough depth – and therefore, many older patients. It is also 
important that MDTs consistently have access to all relevant information about the patients 
they discuss, so that they can make treatment recommendations that are tailored to the 
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patient’s individual circumstances. 
This report also recommended the use of a proforma to ensure that all relevant information is 
included in the MDT’s discussion. This would be completed by the referring clinician and 
would include all relevant diagnostic information, as well as information on patient 
preferences and demographics – including frailty. 54% of MDT members already use some 
form of proforma, but this is inconsistent and there is no national guidance on their content. 
81% of MDT members felt that using a proforma would have a beneficial impact on meeting 
efficiency, since the patient would not need to be discussed a second time. We see this as 
having a particularly strong impact on older patients and therefore: 
Recommendation: UK health services should lead the development of national proforma 
templates, to be refined by MDTs. MDTs should require incoming cases and referrals to 
have a completed proforma with all information ready before discussion at a meeting. 
4.3 THE FLOW OF INFORMATION FROM SECONDARY 
TO PRIMARY CARE 
Our surveys and interviews of primary care staff highlighted a parallel frustration, in the gaps 
in the information flows from secondary care back to primary care. Staff were particularly 
interested in knowing a patient’s diagnosis, treatment recommendations (and rationale), 
prognosis, further assessment and the information given to the patient. Respondents to our 
surveys of health professionals also highlighted the role of primary care in supporting patients 
to manage their comorbidities and thus enabling them to be fit enough to access a greater 
range of treatment options. 
I see my role as a GP is having honest conversations with patients to help them unpick 
this stuff. Now a lot of cancer care teams are very good at providing people with 
information and generally what happens is people will have a huge amount of 
information, feel unable to make a decision and go away then come to their GP with 
questions to talk them through. (National Interviewee) 
Staff also reported that patients would often attend a GP appointment to discuss their 
diagnosis, treatment and its impact on their lives. This often happens soon after patients have 
attended a hospital appointment, meaning that this information is needed very quickly after 
the event. 
I don’t have the information that’s been given to the patient, all I’ve got is the patient’s 
recollection or print-out, I don’t have what the doctor in the hospital was actually 
thinking, because it takes so long for communications to get through. So greater use of 
electronic communication whereby… what’s said to the patient can be said to the GP 
almost simultaneously, because it is not uncommon for somebody to be in floods of 
tears in the car on the way home from the hospital, phoning the GP, asking for an 
urgent appointment to talk things through but the GP didn’t even know they had a 
cancer diagnosis and wouldn’t have been told for days, sometimes weeks. (National 
Interviewee and General Practitioner) 
This is a recognised issue and the standard operating procedure for informing a GP of their 
patient’s diagnosis is often either the same day or within 48 hours of a diagnosis, however the 
extent to which this actually happens is variable.  
We also heard from primary care staff that the diagnosis alone was of fairly limited use. In 
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addition, they would value information about the prognosis, treatment options and wider 
plan in order to support them in their care of the patient.  
Although staff valued forms and electronic systems, the optimal mechanism would be having 
a single person who took the lead on coordinating a patient’s care plan and communicating 
their case back to the GP. For this reason, CNSs were highly valued for their contribution; this 
is especially true for more complex patients, as older people with cancer often are. CNSs relay 
information between primary and secondary care, ultimately helping appropriate decisions 
be made. However, primary care staff also flagged that there is significant local variation 
around CNS availability – and so there is a need for a systematic solution.  
Recommendation: Healthcare providers must ensure that primary care staff are updated on 
the outcome of patient discussions in a timely manner. This should include widespread use 
of digital solutions. 
 
4.4 PRESSURES ON ONCOLOGY SERVICES LIMIT THE 
QUALITY OF DECISION-MAKING AND 
COMMUNICATION BETWEEN OLDER PEOPLE WITH 
CANCER AND THEIR CLINICIANS  
Patients, families and carers can also help provide clinicians with information that can be 
hugely helpful in formulating treatment decisions, and often provide a useful reality check. 
However, clinicians are often reliant on a patient’s assessment of their own abilities – which 
can be inaccurate.  
This inaccuracy can have a variety of causes. For example, patients may overestimate their 
activity levels from a sense of denial of physical decline, or from a desire to convince the 
clinician that they are fit for surgery.  Family members and friends often provide a useful 
reality check in this regard, according to interviewees. Patients can also forget, or not know, 
most of their medical history.  
 Patients forget that the fact they had significant disease twenty years ago may be 
relevant. And of course for a cancer diagnosis, having had a different cancer twenty years ago 
really could matter … The fact that they take all manner of things that they don’t think are 
important and don’t see as medication. They may be getting B12 injections are a classic one – 
people don’t think of that as medication… They forget to tell hospital those sorts of things. 
(National interviewee) 
These findings give positive messages about the involvement of family and carers in the 
decision-making process and highlight the advantages of clear patient information (e.g. 
medication, medical history) being passed on to clinicians. 
Improving communication between older patients and clinicians 
There is strong evidence that shared decision-making (SDM) is beneficial to people with 
cancer4. However, achieving meaningful shared decision-making can be more difficult for 
                                                     
4 CanCORS study, 2015 
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older patients, who are more likely to have multiple conditions and who may be balancing 
decisions about treatment with many other factors. The quality of communication to patients 
was the strongest theme identified by the patients involved in this research as part of 
informed decision-making; this theme was also used as the basis for the patient survey. 
The older people with cancer and caregivers involved in the design and delivery of this study 
saw a continuum of decision-making. At one end was ‘decision-making as consent’, where 
health professionals merely gain consent from patients for the treatment they prefer. At the 
most positive end of the spectrum was ‘decision-making as reaching consensus’, which was a 
lengthier process with more scope for patients to learn about and discuss the different 
treatments options, before making an informed choice.  
In our survey of older people affected by cancer, the most common style of decision-making 
reported (by 40% of respondents) was “the doctor or other health professional led (the 
doctor or other health professionals made all the decisions but took my views into account)”. 
This was frequently reported as a negative experience. 
The current context of time-stretched cancer services are further compromising the ability to 
facilitate true shared decision-making, as evidenced by respondents to our patient survey. 
The risks were given very briefly and I was handed this in written form on the consent 
form.  The side effects of radiotherapy were not explained fully and I found out more 
information for myself and then asked questions. (a patient) 
Mostly, it was assumed that I would do whatever they suggested - whilst I was not 
unhappy with what was being offered, as I knew that there were not a lot of options, I 
do not feel in hindsight that I was given much choice or indeed support in making such 
a choice. (a patient) 
Another respondent reported feeling that questions were ‘tolerated rather than 
encouraged”. In other cases, patients were expected to make a decision, but did not feel they 
had the necessary knowledge to do so.  
Support was there in the form of 'hand-holding' while it was up to me to make the 
decision. Statistics showed roughly the same outcome for surgery or radiotherapy. It 
would have been just as supportive to give me a coin to toss when what I really needed 
was some indication as to which would be better for my particular circumstances. 
Perhaps I was looking for guidance that simply isn't there. (a patient) 
Some clinicians involved in the research also reported patients not wanting to make the 
decision themselves.  
And so the conversation goes something like this you know; ‘now you want treatment, I 
have a choice of treatments, would you like me to tell you about both of them and you 
make your decision or would you like me to make a recommendation?’ And ninety-eight 
percent of patients say ‘you make the recommendation’. (Medical Oncologist) 
These quotes highlight the importance of giving patients all relevant information needed to 
make a decision, but also of flexing the approach according to the patient’s wishes.  
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4.5 COMMUNICATION CHALLENGES 
4.5.1 CONFLICTING INFORMATION 
Many negative response about communication received through our patient survey focused 
on not being able to understand information, and being given conflicting messages. This 
reinforces the importance of coordinating care across the multidisciplinary team and 
presenting a unified message to the patient.  
I was concerned that the surgeon and the oncologist did not seem to have quite the 
same agendas - whilst they superficially work as a team, for example the oncologist 
was very dismissive of the surgical option, which I found confusing. (a patient) 
However, anaesthetists interviewed for this study also acknowledged that on occasion, there 
may well be differences in opinion between the clinicians involved as to the balance of risks.  
So it pays you to know exactly what patients know when they arrive, what they’ve 
been told and where they’re up to… there’s a kind of a golden rule that if you’re going 
to quote figures you must write them down.  So if a surgical colleague has quoted 
figures they should be in his clinic letter, which I will always have read …so I might say 
‘well, actually I’m going to adjust Mr X’s figures because I don’t think I feel quite as 
optimistic as he does’.  So that’s how I’d handle that. (Anaesthetist) 
4.5.2 BENEFIT VERSUS RISK 
As previously discussed, older patients are likely to have to consider a greater number of 
factors in treatment decision-making. Part of this involves balancing the benefit of treatment 
with the risk of a lower quality of life, stemming from long-lasting side-effects of treatment. 
To make these decisions, they must be given the full spectrum of information – but we heard 
from patients involved in the research that this was sometimes not the case, with emphasis 
disproportionately placed on benefits. 
Benefits [of surgery; removal of the tumour] were clear. However, an ileostomy was 
involved and little was said about this leaving me unprepared for the result. (a patient) 
But [I] would have liked more information on the effects of chemo on your brain as I 
was definitely affected by the treatment. And although my mental acuity has improved 
it is not the same as it was. (a patient) 
This picture was not reflected by the clinicians interviewed as part of the research, who 
reported that presenting information on the benefits and risks of different treatment options 
is an important element of ensuring patients have realistic expectations and can make 
appropriate decisions. The success of doing this is likely to vary considerably between 
clinicians.  
4.6 HAVING SUFFICIENT TIME TO MAKE DECISIONS 
Another common theme from this research was the need to have sufficient time to make an 
informed decision. Again, this is felt across cancer services but may disproportionately impact 
older patients because of the complex nature of decision-making. As well as impacting the 
process decision-making, this is likely to affect patients’ broader experience of care.   
Again, I was not able to take everything in at the time and it took quite a while to then 
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calmly go through the carrier bag of leaflets I was handed on the day. (a patient) 
This perspective was reflected by national level, primary and acute care interviewees, who all 
highlighted the importance of giving patients time to think through the implications of 
treatment and the extent of support they are likely to have available.  
This is felt particularly acutely during a consultation, when patients can be sensitive to 
clinicians’ high workloads and are conscious not to ‘take up their time’5. Again, this often 
impacts older people more than younger people, as they may require more time to consider 
options. 
Today I had a patient who has cancer but has other comorbidities … so I had to discuss 
that … and make it clear to them that these are the risk factors, these are the things 
that go wrong … that 20/30 minutes … just gets dragged on to 45 minutes. We can’t 
just stop the consultation because it’s been running out of time. (Anaesthetist) 
At one site observed in this research, a more flexible breast clinic system has been 
implemented. This provides more realistic clinic slots, redressing the widespread trend for 
clinics which always run over time – leading to poor experiences for health professionals and 
patients. 
…sometimes we were here till eight o’clock at night … And it was unfair on the 
patients. It was draining on the staff … and by the time you’re getting to the end of the 
clinic, you know, your energy levels are really sort of hitting low and you sort of have to 
question what have I got to continue to offer this evening… But it’s completely 
different now. So the slots are well spread out, clinics are running to time, patients 
aren’t kept waiting and we’re finishing at a reasonable time as well. (Cancer Nurse 
Specialist) 
Recommendation: Cancer MDT leads and service managers should consider reviewing the 
length of consultation slots, factoring in additional time for more complex patients, and 
providing additional support before, during and after consultations for those who are living 
with frailty or have multiple comorbidities. 
4.7 NATIONAL PRESSURES ON DECISION-MAKING 
TIMELINES 
Cancer treatment decision-making in the UK is also shaped by national treatment targets. 
Several members of cancer MDTs interviewed for this study raised the issue of national 
treatment targets creating unhelpful pressure, for two reasons: firstly, through putting 
patients under pressure to make a quick decision, but secondly by limiting opportunities for 
testing patients’ likelihood to be able to tolerate treatment, and then for tailoring their plan 
accordingly. 
The other issue is that with the government targets for making a decision, often people 
are having to make a decision quite quickly and I think you know sometimes we just 
need to give people more time to help support them make the right decision for them. 
(Cancer Nurse Specialist) 
They’re guidelines not tramlines and I think people get so caught up in that, that you 
                                                     
5 Joseph-Williams et al, 2014 
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forget the patient may not want to work in the timescale that the guidelines say. 
(National interviewee)  
 And some people need to see family; they need to get daughters and family over from 
Australia or America. They want to see them before they go through an operation that 
they may not survive. ..So I think the push to deliver an 18 week pathway sometimes 
detracts from what that patient’s needs are. (Anaesthetist) 
Furthermore, national targets can also mean that there are limited opportunities to spend 
time testing and retesting people for how likely they are to tolerate treatment, and 
optimising them if necessary. This has been echoed in research, which has found that service 
targets that focus resource solely on cancer can disadvantage patients with complex wider 
needs, as individual clinicians may struggle to deliver effective treatment plans without 
breaching targets156. 
 … there’s good evidence to show that if you try and optimise people…you can improve 
their CPEX testing. So we haven’t got time to do that for cancer surgery because 
obviously they’re within a window that we have to see them. (Anaesthetist) 
Recommendation: in ongoing reviews of cancer waiting times targets, NHS England and 
devolved health services should consider ways to ensure optimal treatment access, a 
positive experience and better outcomes for older people with cancer. 
4.7.1 IMPROVING THE PROCESS OF DECISION-MAKING 
Older people involved in this study identified several means of improving the process of 
treatment decision-making, such as charity-run cancer support services and peer advocacy. 
‘I was utterly confused [after diagnosis] and couldn’t understand why the world was 
still turning really. It was a break through meeting my advocates. I have been an 
advocate myself for the last two years. The advocates offer a caring approach and they 
have been there themselves, we are all on the same level. My third advocate was a 
great match for me personality wise. They went with me to hospital appointments and 
provided transport and help me to face the reality.’ (Older person with cancer and co-
researcher) 
Some people also spoke about the value of improving communication through a summary 
card, held by each patient. This was included as a recommendation of the Oxfordshire 
‘Cancer, Older People Peer Advocates patient experience Group’ report to Healthwatch6. The 
card would include a summary of diagnosis, treatment recommendations, current 
medications and the details of the professional team assigned to the older patient, as well as 
how to contact them.   
  
                                                     
6 Young/COPA Peer Advocates Patient Experience Group, 2016 
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5. THE CANCER WORKFORCE 
COULD BETTER SUPPORT THE 
NEEDS OF OLDER PATIENTS 
Cancer services in the UK are experiencing severe workforce gaps across many key 
professions, which is having a real impact on the ability to diagnose and treat cancer quickly, 
as well as to give patients the best possible experience of care157.  
There are also broader issues relating to the preparedness of the workforce to treat the 
growing number of older patients, including deficits in education, knowledge and attitudes 
and in the development or specific roles and services that meet older people’s needs158. For 
example, a 2013 survey of UK medical oncology trainees found that only 27.1% were 
confident in assessing risk to make treatment recommendations for older patients, compared 
to 81.4% being confident about treating younger patients159. 
For people with complex needs, it is critical that health professionals with specialist expertise 
are available to support them throughout treatment decision-making and treatment itself. 
There is also some evidence of benefit in providing additional specialist support, targeted to 
groups of older people with complex needs, who are at risk of undertreatment160.  
5.1 EXPERTISE IN THE MDT 
As previously discussed, just 14% of MDT discussions observed during past CRUK research 
included information that did not directly relate to the patient’s tumour161, for example 
comorbidities, social needs or treatment preferences. This is a direct result of the growing 
mismatch between an MDT’s capacity and the demand they face, which leads to severe time 
pressure on their discussions. This is likely to have a particularly significant impact on older 
patients, who are most likely to have complex social and medical needs.  
One of the issues for all MDTs is managing to comprehensively get through the cases in 
a meaningful way in which we [healthcare professionals] make the right selection of 
treatment strategies when you’ve maybe got… forty patients plus at an MDT.  (Clinical 
oncologist)  
As well as a proforma, ensuring an MDT discussion is centred around the needs of an older 
patient could be ensured by including relevant specialists in the meeting. However, MDT 
members responding to our survey expressed concern that their MDT did not routinely 
include specialists who could add value to a discussion about an older patient, such as social 
workers, occupational therapists, physiotherapists, dieticians, and pharmacists. 
In one MDT meeting observed for this research (SCOPES), one member of staff – a lead nurse 
– attended the meeting, representing a smaller multidisciplinary team of allied health 
professionals who had completed a comprehensive geriatric assessment. They could then 
feed the results of the assessment back to the MDT and suggest the implications for 
treatment, and likewise could feed the MDT’s recommendation back to their team of allied 
health professionals.  
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In another site, a joint surgical-oncology clinic had been established so that patients could see 
both the surgeon and an oncologist for a fully comprehensive discussion to compare surgical 
options with radiotherapy and chemotherapy. This was introduced to prevent patients being 
recommended for surgery, found to be unfit and then having to wait again to start 
radiotherapy. In this case, the clinicians found it valuable to bounce ideas off each other when 
finalising their plans. 
 … we always take another opinion … we don’t hesitate to ring or even because we 
have two of us doing the clinic always pop in next door and say this is what I think and with 
this information I am giving do you think it is that or do you think differently? (Anaesthetist) 
 
5.2 SPECIALIST CANCER NURSES 
Clinical Nurse Specialists (CNS) play an important role in cancer care, supporting good patient 
experience162 and acting as a ‘key worker’ throughout diagnosis, treatment delivery and 
palliative care163. As such, appreciation of CNSs was raised consistently throughout this 
research.  
 The older people with cancer surveyed generally reported that they had been well supported 
by health professionals, with specialist nurses particularly appreciated. Nurses were also 
recognised for their role in providing practical advice about managing their treatment. 
The consultant made clear notes that I could take away. The specialist nurses followed 
up with clear and necessary advice. (a patient)  
However, this was not uniform – reflecting the significant challenges faced with CNS staffing. 
This is a concern – the 2015 Cancer Strategy for England recommended that all people with 
cancer should be given a named CNS or key worker contact164; this is also included in NICE 
guidelines.  
When I was first diagnosed 7 years ago there was no CNS in haematology at our local 
hospital and until I was referred elsewhere, I didn't realise these amazing nurses 
existed. Fortunately, we have a wonderful CNS now who is available by phone or e-
mail whenever needed. (a patient)   
Whilst the proportion of patients in England having access to a CNS has risen from 84% in 
2010 to 90% in 2016165, there is still room for improvement and still variation across 
geographies and across different cancer sites. 84% of patients in Scotland reported access to 
a CNS in 2015/16166; in Wales in 2016, 81% reported access and in Northern Ireland in 2015, 
this figure was just 72%. Staffing issues were also recognised by national interviewees, with 
this seen as a particular challenge for rarer cancers.  
I mean the cancer nurses are fantastic where they exist and patients are directed to 
them, that’s great. The problem is that they tend to be there for the bigger, more 
common cancers, so the colorectal teams are often fantastic, the breast cancer teams 
are fantastic. But where it’s more unusual cancers or where the cancer seems to be 
more of a superficial thing, I mean I come across this less for skin cancer things or less 
for some of the other gynaecological cancers. Frequently there’s just one of these 
nurses in a team and therefore once they’re on holiday or they’re sick there’s no back 
up, there’s nothing else, there’s nobody else who can step in. (National Interviewee) 
This has an impact on the ability of a CNS to support patients adequately. For example, past 
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research has shown that over half of prostate CNSs felt they didn’t have the time to attend to 
the holistic needs and psychosocial assessment requirements of their roles167. 
Furthermore, the role of a CNS is highly variable and the job title and expectations can be 
inconsistent168. CNSs often fill service gaps in their local centres, rather than doing the work 
that best fits their expertise. A survey from CRUK research into the non-surgical oncology 
workforce found that 50% of CNSs did not feel they had enough patient-facing time and were 
consistently working an average of 5 additional hours each week – on average, 15% of their 
working hours. 
Recommendation: Health Education England, and its equivalents in the devolved nations, 
should use the Cancer Research UK ‘best practice treatment model’ to project required 
workforce numbers based on patient demand, not on affordability. Organisations should 
also consider the specific needs of older people with cancer in all workforce plans.  
Recommendation: Government should provide investment to support Health Education 
England’s phase 2 cancer workforce plan, which will say how many staff will need to be 
trained and employed to deliver effective cancer care beyond 2021. 
 
5.3 GERIATRICIANS 
Interviewees across primary and secondary care also raised the potential benefit of involving 
elderly care specialists. GPs commented that if there were concerns around frailty and an 
older person’s capacity to withstand investigative tests, they would seek further advice from 
local elderly care specialists or geriatric consultants. These measures to avoid simple ‘non-
referral’ may be important steps in the pathway to improve access to treatment for older 
people.  
If they are very frail I would ask for a [geriatric] consultant review rather than send for 
invasive diagnostic tests (General Practitioner) 
 Whilst MDT members reported that it was not the norm for geriatricians to attend MDT 
meetings, some interviewees noted that they were able to refer patients to a geriatrician. 
However, few had done this in practice and the value of this was contested.  
…wouldn’t actually think [a] Care of the Elderly physician would know very much 
about lung health or how that feeds into our ability to give radical treatments… I could 
see the value of they knew the patient and they had some thoughts about their wishes 
or their home circumstances or things that you could do to improve the performance 
status. (Clinical oncologist) 
However, others saw increasing value in involving geriatricians in treatment decision-making; 
in a similar way to how palliative care has been recognised and expanded over recent years. 
Many years ago there was a little bit of palliative medicine and a few palliative care 
physicians and no palliative care nurses – where is there a hospital now without one, 
or two, or three or four? It’s all grown up and my feeling would be that in time we’ll 
see a similar thing for older people – there’ll be leaders for that in each department.’ 
(National Interviewee) 
Current evidence suggests that CGAs should be led by elderly care specialists, as part of a 
multidisciplinary team. For example, the Macmillan/Department of Health Older Persons Pilot 
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demonstrated that geriatrician liaison was the most effective way of delivering CGA169. Other 
research has also highlighted the value of including elderly care specialists in cancer decision-
making, although it does not happen routinely. 
Elderly care specialists are experienced in co-managing multiple health conditions and 
polypharmacy, as well as engaging and mobilizing a range of community-based health 
and social services to provide practical support, but they are rarely involved in decision-
making related to cancer treatment. (Maher 2016170) 
There are a number of initiatives which seek to embed input from elderly care specialists into 
cancer treatment decision-making. For example, Nottingham University Hospital have a 
geriatrician-led CGA process that feeds directly into MDT meetings (see SCOPES example in 
section XX).  
 
  
Advancing Care, Advancing Years 55 
6 WE NEED TO IMPROVE HOW 
INNOVATION IN TREATMENT 
AND CARE REACHES OLDER 
PEOPLE WITH CANCER 
Research is the key to improving outcomes for all people affected by cancer. However, older 
patients are typically under-represented in clinical trials171, which can have strict inclusion 
criteria based on chronological age, comorbidities or cognitive ability. These factors combined 
mean that there is often relatively limited evidence on the specific effects of treatment on 
older patients.  
 
This means that decisions about treatment for patients with comorbidities – and therefore 
often older patients – cannot always be based on strong evidence. At least, not in comparison 
to decisions for their younger or otherwise fitter counterparts.   
6.1 OLDER PATIENTS ARE UNDER-REPRESENTED IN 
CLINICAL TRIALS 
Older people are in general under-represented in clinical trials172, including in cancer173. This 
is particularly acutely felt for “older old patients”, who are typically the most frail and 
comorbid. This was also recognised by our clinician interviewees: 
The most important thing is we don’t have any evidence for such patients… the number of 
patients who are [in] clinical trials above 75 years of age is far and few between and no 
meaningful conclusions can be made on that. (Medical oncologist) 
The discrepancy between a trial population and a “real” clinical population has major 
implications for how applicable evidence from clinical trials is in the clinic. Older patients can 
respond very differently to treatment, due to a range of factors174. For example, age-related 
physiological changes can impact how a drug works in the body. Older patients may also 
experience different or worse side-effects, which may not have been predicted from the 
younger trial population. The effect of this was summarised by an expert committee of the 
European Medicines Agency: “the drugs we are using in older people have not been properly 
evaluated”175. 
More could still be done to gather evidence, including boosting numbers of older patients in 
trials – but also doing research that enables patients with comorbidities or frailty to receive 
optimal treatment, that accounts for the impact of comorbidities and frailty.  
There are several reasons for this under-representation; these are mostly a combination of 
stringent eligibility criteria and concerns from clinicians about subjecting older – or frailer – 
patients to rigorous treatment. There are also other complicating factors, for example 
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challenges in gaining informed consent from patients with cognitive issues, or difficulty 
assessing outcomes in patients who already have several comorbidities176. Further practical 
factors also exist, for example the inaccessibility of trial consent forms177.  
There is appetite for change: 70% of European health professionals responding to the 
PREDICT study in 2014 did not did not believe the present arrangements for clinical trials 
relating to older people to be satisfactory, and 60% believed that either European or national 
regulation of clinical trials should be amended to ensure greater representation of older or 
less fit patients178.  There have also been efforts to address this, for example the EMA’s 2011 
Geriatric Medicines Strategy179 or the EU-funded PREDICT initiative (Increasing the 
Participation of the Elderly in Clinical Trials), which proposes ways of boosting recruitment of 
older patients to clinical trials.  
Inclusion of a geriatric patient group may also add to the variability of any endpoint, 
potentially resulting in decreased effects if the study is not adequately powered. This may 
result in a need for larger studies of increased complexity and likely longer drug development 
timelines, unless alternative approaches are also considered (including post-authorisation 
data collection, as discussed in the next section).  
Most clinical trials funded by Cancer Research UK do not have an upper age limit, when age 
limits are applied, researchers are asked to justify the boundary selected. Exclusion criteria 
relating to comorbidities or patient fitness are used in some trials where they risk 
confounding results or adding a safety risk, however, and comorbidities do increase with age. 
CRUK also fund some trials that ask specific questions about treatment for older patients, or 
patients who are less fit. 
Recommendation: Research funders should explore how to ensure more proportionate 
recruitment of older people with cancer into clinical trials, and how to ensure that research 
addresses any evidence gaps in the effectiveness of treatment in older patients, or those 
with comorbidities more broadly.  
 
6.2 APPROVING NEW TREATMENTS 
As well as reviewing clinical trials, there is scope for making changes to the process of 
approving new treatments so that it better supports older people with cancer by gathering 
more evidence that applies to those patients. This should include embedding the patient 
perspective in approvals, but also consideration of how the process could incorporate 
evidence of a treatment’s effectiveness in a more varied patient population – or at least 
including more flexible criteria in drug assessments.  
35% of respondents to our survey of MDT members felt that a lack of clinical evidence about 
the efficacy of treatment in an older population was a barrier to treatment. This is particularly 
problematic in cancers where there is a poorer understanding of the disease and its 
progression, and this can make it difficult for clinicians to assess the risks of treatment and to 
weigh that up against the potential benefit to the patient. However, this is likely part of a 
broader issue about evidence in comorbid populations, rather than being related solely to 
chronological age.    
There is also scope for making changes to the process of approving new treatments so that it 
better supports older people with cancer, who may value outcomes other than just improving 
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survival – such as maintaining a good quality of life, their independence and cognition180. For 
example, national drug approvals should consider incorporating a broader range of evidence, 
including impact on quality of life – which was recommended in the Life Sciences Industrial 
Strategy181, although the recommendations were not specifically targeted towards older 
patients.  
In the longer term, we encourage UK health services to explore the use of flexible pricing 
mechanisms such as outcomes-based pricing, in which the price of a drug can be reviewed at 
agreed stages and aligned directly to patient benefit, being increased or decreased based on 
emerging new data. This would ensure pricing and access decisions are grounded in the real 
experiences of patients. To take this forward, Cancer Research UK are exploring the feasibility 
of outcomes-based pricing through a commissioned research project, in partnership with the 
Greater Manchester Health and Social Care Partnership. 
6.2.1 HIGH-QUALITY DATA 
A key enabler to this is robust, routinely collected data about cancer treatment and 
outcomes. This is not an age-specific issue as it would significantly improve our ability to 
understand the effects of treatment on all patients. All UK organisations responsible for 
collecting health data should ensure significant resource is provided for improving the quality 
and completeness of treatments datasets. Having robust data about treatments and 
outcomes would enable more in-depth analyses of the extent of variation in access to 
treatment and outcomes for older patients, which could supplement clinical trial data and 
support efforts to benchmark services.  
 
Recommendation: National drug appraisal bodies should explore what alternative metrics 
could be considered during appraisals that would be more relevant to all patients, including 
older patients – such as quality of life and activities of daily living. 
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APPENDIX 1: METHODOLOGY 
RAPID EVIDENCE ASSESSMENT 
The research began with a rapid evidence assessment (REA), focussed on the identification of 
evidence to direct and refine the research design. Initial searches were undertaken by HSMC’s 
specialist library and documents were identified via the following databases:  Social Science 
Citation Index; Ageinfo; ASSIA; HMIC; Medline; Embase; Cinahl; Social Care Online. Where 
particularly relevant literature was identified in this review, additional searches were 
conducted of the reference lists of those documents.   
SURVEYS 
Three surveys were carried out, gaining a total of 197 responses. Each survey gathered 
quantitative evidence using fixed response questions but also contained a number of open 
ended questions for free text responses. Quotations from these free text survey responses 
have been used throughout the report. To achieve a wide reach for both of these surveys, a 
‘snowballing’ approach was also employed, with recipients encouraged to share the survey 
link with their colleagues and contacts.  
Full text of surveys is available on request. The surveys were as follows: 
Primary care survey: this focused on how primary care responds to older people with 
suspected cancer, particularly what information is passed on for consideration at the point of 
referral and how the role of primary care in cancer care may develop in future.  We received 
98 responses to the survey. The survey was designed with input form Macmillan Cancer 
Support and piloted with 12 Macmillan GPs who shared feedback on both the design and 
content of the survey. The survey was distributed through Macmillan GPs, Doctors.net, 
Cancer Research UK primary care facilitators and engagement team and the Royal college of 
GPs. 
MDT survey: this focused on what information and assessments are being used to make 
treatment recommendations, and what subsequent decision-making support is offered to 
older people.  The survey was distributed through networks of various Royal Colleges. We 
received 57 responses to the survey. 
Patient survey: a patient survey was designed to understand the experiences and 
perspectives of older people who have been treated for cancer and how they contribute to 
their treatment decisions. The survey design was led by our co-researchers. Distribution was 
through Cancer Research UK’s patient involvement newsletter and webpages, Cancer Chat 
and Macmillan involvement network. 
INTERVIEWS AND OBSERVATIONS 
The experiences and views of national level interviewees were captured in interviews, with 
representation across all UK countries. Seven local case studies explored the views of health 
professionals involved in the treatment decision making process. At a local level, interviews 
were carried out with MDT members, staff who were involved in assessing and supporting 
but not involved in MTDs (AHPs and anaesthetists) and primary care staff. Two devolved 
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nations will be represented in this sample.  
It should be noted that this study sampled case study sites to capture practice representative 
of cancer services for all older people, rather than to identify best practice. As such, including 
innovation was just one aspect of site selection, alongside: distinctive older population 
demographics; BME populations; rural poverty; a range of cancer types; primary, secondary 
and tertiary services; and inclusion of different staff groups (radiologists, anaesthetists etc.). 
Semi-structured interviews were undertaken at case study sites with 40 health professionals. 
Separate topic guides were designed for staff primary care and acute settings. Topic guides 
were informed by the evidence review findings and aimed to pick up on the survey themes 
and explore them in greater depth. All interviews were carried out either face-to-face or by 
telephone, after gaining participants’ consent. 
Three observations were undertaken; two MDT meetings and a half day multidisciplinary 
clinic. Non-participative observation can be a valuable unobtrusive method of data collection 
and can help to provide context and a richer understanding of interaction and the nature of 
services. The research team designed a set of observational cues that addressed their 
research questions and topic directly. 
All interviews were recorded and transcribed to allow for thematic coding and analysis. 
Observational notes were incorporated into the analysis. This involves the initial identification 
of analytical themes derived from the research questions and the literature, to which 
additional themes are added as new insights emerge from the data. The value of this 
approach is that it is particularly well suited to the problem-oriented nature of applied and 
policy relevant research, whilst also allowing for an analytical process which remains 
grounded in and driven by participants’ accounts.  
PATIENT INVOLVEMENT 
Recognising the significance of patients and carers in the decision-making process, we also 
recruited a group of seven older people affected by cancer as co-researchers. Across three 
half-day workshops, this group designed a patient survey and provided guidance on the 
interpretation of findings, adding an essential perspective to our overall analysis. 
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APPENDIX 2: PATIENT MESSAGES 
TO THE NHS  
The following messages were contributed by the older people consulted for this research. 
‘What do you want to say to the NHS about involving older people in treatment decisions 
about cancer?’ 
A lot of older people don't understand the treatments so explaining them all helps. And giving 
options and some pamphlets about types of treatment can make them feel better. 
Age is just a number! What should happen for every patient with cancer is a full explanation 
of the diagnosis and the treatment options, including no treatment if that is appropriate, and 
help in making that decision.  
Be clear about the after-effects and what support could be available if living on own. Offer 
information that helps cope with the trauma of being told and how to manage post-op.  
Be thoughtful, patient and kind.  
Clear explanations of risks/ side effects and benefits of the particular treatment. Possible 
options of other treatments. Patient and family to feel supported during and importantly 
after decision making. 
Clear supportive communication.  
Don't patronise and don't make assumptions!  
Employ enough staff to make consultations less hurried. It would be helpful to see the same 
doctor each time, though I know this is next to impossible. At least it helps if they have 
actually read your notes before you get in there. 
Encourage them to bring someone along to appointments and treatment. Ask for their 
opinions, listen to them, respond to their questions. Don't be paternalistic. Make sure they 
have all the help they need at home and help with transport to hospital. Introduce them to 
local support groups. 
Give access to as much information as possible about effects  
Give them a clear choice i.e. We can do A for you, or B for you, or C, for you. Or a combination 
of them. Sadly at the moment the consultant TELLS the patient what is going to happen, 
offering the patient no choice. 
Give them enough information in terms ordinary non-medical people can understand. I had 
things given to me in Laymen’s terms, but I do know of some people where the medical 
jargon was used and understandably they got very confused.  
I am 68 and I could not have wanted a better Dr everything was explained so I understood 
I feel all adults should be involved in treatment decision whatever age a patient is  
I find this question rather offensive, as well as grammatically flawed. The question seems to 
confuse and conflate being aged over 55 with having mental capacity issues. "Older people", 
like any other age group, require accurate, unbiased, objective information - including 
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potential side effects and average survival times with and without each treatment - in order 
to make informed decisions about their treatment. People with mental capacity issues, 
regardless of their age, may need such information to be presented in a more easily 
understood format - in line with the requirements of the Mental Capacity Act 2005.  
I have been treated with respect during my treatment, but after care support could be 
improved.  
I have nothing but praise for the NHS and the way our hospital involves older patients in their 
treatment.  
I really think it's important to stress the side effects of surgery, radiotherapy and chemo. 
Unfortunately people watch the TV where the side effects are brushed under the table. The 
only issue seems to be losing your hair! For e.g. the ability of a 40 year old to recover from a 
mastectomy is going to be better than an 85 year old. Also things like neuropathy are not 
covered at all. 12 years since my first tranche of chemo and I still have quite painful 
neuropathy in my fingers. My sister finished chemo and radiotherapy in February and has lost 
all feeling in her foot and is effectively very disabled now. She has been told her foot may 
never recover. No one told her this. Also, there are NO rehabilitation services, no Macmillan 
in many parts of the country. So a fit very elderly person will recover from surgery, but if 
you've spent the last 30 years sitting in a chair and watching telly then you won't recover at 
all.  
Involve them all along the way.  
It is crucial to do so. It may be the first time the person has not been in control and a degree 
of patient influence is essential. 
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